

Form PTO-1390  
(REV 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

0652.2090000

U.S. APPLICATION NO. (IF KNOWN, SEE 37 C.F.R. § 1.5)

To be assigned 09/555574

INTERNATIONAL APPLICATION NO

PCT/EP98/07695 ✓

INTERNATIONAL FILING DATE

28 November 1998 ✓

PRIORITY DATE CLAIMED

4 December 1997 ✓

TITLE OF INVENTION

Transfection Particles

APPLICANT(S) FOR DO/EO/US


BEHR, Jean-Paul; BLESSING, Thomas; WAGNER, Ernst; SCHUELLER, Susanne ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 372(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:  
37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (in duplicate).

U.S. APPLICATION NO (if known, see 37 C.F.R. 1.50) <b>09/555574</b>		INTERNATIONAL APPLICATION NO PCT/EP98/07695		ATTORNEY'S DOCKET NUMBER 0652.2090000	
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS    PTO USE ONLY</b>	
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$970.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$840.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$690.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$670.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... <b>\$ 96.00</b>				<div style="border: 1px solid black; padding: 5px;"> <b>ENTER APPROPRIATE BASIC FEE AMOUNT</b> = \$ 840.00         </div>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="border: 1px solid black; padding: 5px;">         \$ 130.00       </div>	
Claims	Number Filed	Number Extra	Rate		
Total Claims	65 - 20 =	45	X <b>\$18.00</b>	\$ 810.00	
Independent Claims	1 - 3 =	0	X <b>\$78.00</b>	\$ 000.00	
Multiple dependent claim(s) (if applicable)			+ <b>\$260.00</b>	\$ 260.00	
<b>TOTAL OF ABOVE CALCULATIONS</b>				=	\$ 2040.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must be filed. (Note 37 CFR 1.9, 1.27, 1.28)				\$	
<b>SUBTOTAL</b>				=	\$ 2040.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
<b>TOTAL NATIONAL FEE</b>				=	\$ 2040.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property				+	\$
<b>TOTAL FEES ENCLOSED</b>				=	\$ 2040.00
				<b>Amount to be:</b>	\$
				<b>refunded:</b>	
				<b>charged:</b>	\$
a. <input checked="" type="checkbox"/> A check in the amount of <b>\$ 2040.00</b> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0036</u> . A duplicate copy of this sheet is enclosed. <b>NOTE: Where an appropriate time limit Under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: <b>STERNE, KESSLER, GOLDSTEIN &amp; FOX P.L.L.C.</b> 1100 New York Avenue, NW, Suite 600 Washington, D.C. 20005-3934				<div style="text-align: center;">   <small>SIGNATURE</small>  <b>Raz E. Fleshner</b>  <small>NAME</small>  <b>34.331</b>  <small>REGISTRATION NUMBER</small> </div>	

34/PART

09/555574

422 Rec'd PCT/PTO 01 JUN 2000

## Transfection particles

### Field of the invention

The present invention relates to the field of nucleic acid delivery into higher eucaryotic cells, in particular for applications in gene therapy. The invention provides new transfection particles that are useful for transfecting higher eucaryotic cells *in vitro* and *in vivo*.

### Background of the invention

A critical step of modern recombinant nucleic acid technology is the efficient transfection of cells *in vitro* and *in vivo* with foreign genetic material.

Commonly, recombinant viruses are used for efficiently carrying foreign genetic material into cells *in vitro* and *in vivo* (Mulligan, 1993). Recombinant viruses are often cell specific which may be of advantage or disadvantage depending on the individual experiment. In addition to the foreign material they also carry their own genetic material and are highly prone to mutational changes during replication. In organisms with immune systems a further disadvantage of viruses *in vivo* is a possible unwanted immune response triggered by virus particles such as capsid antigens. Last but not least, even today the preparation of recombinant viruses for gene transfer is an expensive and laborious task.

Virus-free nucleotide particles are also available for transfecting cells. For this purpose, complexes of nucleic acid molecules, counterion-condensed by cationic polymers (Tang and Szoka, 1997) or cationic lipids (Labatmoleur et al., 1996), are employed for genetic transfer. These polymer and lipid condensed nucleic acid molecules are efficient at transfecting cells in

culture. Since these counterion-condensed nucleotides generally lead to multimolecular and polydisperse aggregates they are very poor at diffusing within a tissue or escaping blood vessels.

Cationic detergents too have been shown to condense DNA into discrete particles (Behr, 1986) which, interestingly, can consist of only a single nucleic acid molecule (Melnikov et al., 1995). However, detergents have a much higher water solubility than lipids and their fast release into the environment induces DNA-decondensation and detergent-related cytotoxicity. As a consequence, this class of amphiphiles is unable to transfect cells *per se* (Behr, 1993).

Because of the importance of gene delivery for modern biological and medical research and therapy, for example gene therapy, there is a growing demand for stable, inexpensive and convenient transfection systems that are useful for *in vitro* and *in vivo* applications.

### Summary of the invention

It was the object of the present invention to provide a novel transfection system for delivering nucleic acid into higher eucaryotic cells that circumvents the disadvantages of the cationic transfection systems of the state of the art.

The present invention provides particles for transfecting higher eucaryotic cells with nucleic acid molecules *in vitro* and *in vivo* comprising one or more nucleic acid molecules condensed by organic cationic molecules, said particles being obtained by complexing the nucleic acid molecules with identical or different organic cationic precursor molecules without crosslinking nucleic acid molecules, and covalently linking the precursor molecules to each other on the nucleic acid template.

The particles of the invention are, due to the use of small cationic precursor molecules instead of larger cationic molecules, essentially free of aggregated nucleic acid. Furthermore, the particles are stabilized by the dimeric or oligomeric cationic molecules formed by covalent linkage of the precursor molecules.

In the following, unless otherwise defined, for simplicity, the term DNA is used for both DNA and RNA.

The stability of the particles should be reversible in order to make the DNA available for its desired biological effect in the cell. To this end, in a preferred embodiment of the invention, the linkage between the cationic molecules is reversible under the conditions that the particles are faced after entry into the cell. The break of the linkage may be triggered by the slightly acidic environment and/or the reducing conditions and/or enzymatic machinery of the cellular compartments, e.g. the endosomes.

The cationic molecules that condense the DNA are obtained by covalently linking the cationic precursor molecules.

Cationic precursor molecules according to the invention are defined in that they are building blocks for the preparation of the cationic molecules that keep the DNA condensed.

The general concept of the invention requires one or more at least bifunctional precursor molecules that are on the one hand cationic in order to complex nucleic acid molecules essentially without aggregating or crosslinking it, and on the other hand capable of covalently linking to identical or different cationic precursor molecules of the particle structure for stabilizing that particle.

A function for covalently linking to identical or different cationic precursor molecules for stabilizing a novel transfection particle can be characterized by different and complementary functions or identical functions. An example of an identical function is a thiol that is capable of providing a disulfide bridge between identical or different precursor cationic molecules.

Depending on the number of functions for linking on a single cationic precursor molecule the cationic molecules can be dimers or oligomers of different or identical precursor molecule. Therefore, the invention also relates to transfection particles characterized in that the cationic molecules are prepared from demised or oligomerized identical and/or different cationic precursor molecules.

The cationic function for condensing nucleic acid molecules is generally a basic function that acquires an additional hydrogen under physiological conditions and therefore becomes positively charged. An example of such a cationic function is an amino function or a derivative thereof. Alternatively, the cationic function is a quarternaryzed amine which does not require protonation.

In a preferred embodiment of the invention, the precursor molecules are cationic detergent molecules that satisfy the above-defined requirements.

In this preferred embodiment, the invention is based on the consideration of the basics of supramolecular chemistry and takes advantage of the essential features of two types of DNA delivery agents (cationic surfactants on the one hand and cationic lipids on the other hand) towards the formation of stable transfection particles reminiscent of viruses. Exemplified for this preferred embodiment, the principle of the invention is schematically depicted in Fig. 1: anionic DNA molecules are condensed individually with an appropriately designed cationic detergent and the resulting neutral

particles are 'frozen' by chemically converting the detergent (the cationic precursor molecule) on the template DNA into a lipid via air-induced dimerization.

The detergent molecules of the invention comprise a cationic polar part, an unpolar part and a reactive function for linking to other detergent molecules. When two or more detergent molecules are linked to each other the detergent character of the original precursor molecules is reduced and they are then defined as lipids because of their lipophilic character and structural similarity to lipids. At this point the reader should be reminded that transfection particles prepared by adding plain lipids to nucleic acid molecules result in large multimolecular and polydisperse aggregates (Labatmoleur et al., 1996) and are not part of the claimed invention.

In a further aspect, the present invention is related to transfection particles wherein the cationic molecules are lipid molecules prepared from detergent molecules linked to one or more identical or different detergent molecules in the presence of nucleic acid molecules.

In a preferred embodiment the invention relates to transfection particles wherein the cationic molecules are prepared by dimerization or oligomerization of detergent molecules. Obviously, the detergents can be identical or different in structure.

In general, cationic detergent molecules for use as cationic precursor molecules can be characterized by their distinct functional features.

In a further aspect of the invention transfection particles are characterized in that the cationic detergent molecules comprise:

- a) at least one function for binding to one or more other detergent molecules,

- b) at least one lipophilic residue,
- c) a non-toxic recipient backbone,
- d) a cationic group for binding to DNA.

Functional residues for binding to precursor molecules are, for example but not limited to, thiol residues that react to provide disulfide bridges (-S-S-), acid hydrazides and aldehydes that provide hydrazones (-C=N-N-), amines and aldehydes that provide Schiff bases (imines, -C=N-), and amines that react with ethylene residues that are suitably substituted (e.g. halides) to provide enamines (-C=C-N-).

In this respect, the transfection particles are preferably characterized in that the function of the cationic detergent molecules for binding to other detergent molecules is selected from dimerizable and polymerizable functions, such as thiols, acid hydrazides, aldehydes, amines, and ethylene residues that are suitably substituted to provide enamines.

Preferably, a transfection particle is characterized in that the lipophilic residue of the detergent molecule is selected from lipophilic amides, esters or ethers. The lipophilic functions of the cationic molecules are critical when using detergents as precursor molecules since the lipophilic residues determine the critical micelle concentration of the detergent precursor that is suitable to provide discrete particles at a desired concentration. The higher the desired DNA concentration, the higher the c.m.c. of the detergent needs to be.

For binding to nucleic acid molecules the preferred functional residues of cationic molecules and especially for detergent molecules are amines or



other basic and cationic derivatives thereof. Suitable amines and derivative are discussed further below.

Preferably, a transfection particle of the invention is characterized in that the function for binding to nucleic acid molecules is selected from an amine or derivative thereof.


The amino functions suitable for the invention depend on their ability to provide positive charges for binding nucleic acid molecules reversibly by charge dependent ionic forces. The ability of amines and derivatives to be positively charged under physiological conditions depends on the structural proximity of the amine. Some structures with close and strong electron drawing substituents may therefore not be basic enough under physiological conditions. Preferably, amino functions of cationic molecules of the invention are strongly basic. One very basic and physiologically acceptable amino function is guanidine which is especially useful for the cationic molecules of the invention. A further example for a suitable amino function is amidine. Both of these functions exhibit a strong interaction with phosphate diester groups.

Preferably, a transfection particle of the invention is characterized in that the function for binding to nucleic acid molecules is guanidine.

The requirements for the recipient backbone for detergent molecules according to the invention are obvious, convenient to prepare and non-toxic to cells.

In a preferred embodiment, the invention relates to transfection particles

wherein the cationic precursor molecules correspond to general formula I



(I)

wherein

$R_1$  denotes (C<sub>1</sub>-C<sub>10</sub>-alkylene)-SH, wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

$R_2$  denotes -NR<sub>4</sub>R<sub>5</sub>, -NHR<sub>4</sub>R<sub>5</sub><sup>+</sup>, -N(R<sub>4</sub>)<sub>2</sub>R<sub>5</sub><sup>+</sup>, -C(=NR<sub>4</sub>)NR<sub>5</sub>R<sub>6</sub>, -C(=X)-C<sub>1</sub>-C<sub>10</sub>-alkylene, wherein the alkylene radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four dialkyl amino groups or a thiomonosaccharide;

$R_3$  denotes C<sub>5</sub>-C<sub>30</sub>-alkyl, straight chained or branched and optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>5</sub>-C<sub>30</sub>-alkenyl, straight chained or branched having up to ten C=C-double bonds and is optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>5</sub>-C<sub>30</sub>-alkinyl, straight chained or branched having up to ten C≡C-triple bonds and is optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>6</sub>-C<sub>10</sub>-aryl optionally substituted, or

C<sub>7</sub>-C<sub>16</sub>-aralkyl optionally substituted, or a

C<sub>5</sub>-C<sub>30</sub>-alkyl-chain interrupted by up to 10 amino groups -NR<sub>4</sub>- and having optionally an amino-group which is optionally substituted by an amino acid;

R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> denote independently from each other hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

X denotes O or S;

Y denotes C=O or C=S and

Z denotes O, S or -NR<sub>4</sub>-.

In a more preferred embodiment, the invention relates to transfection particles characterized in that the cationic precursor molecules correspond to general formula I wherein

R<sub>1</sub> denotes (C<sub>1</sub>-C<sub>6</sub>-alkylene)-SH, wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

R<sub>2</sub> denotes -NR<sub>4</sub>R<sub>5</sub>, -NHR<sub>4</sub>R<sub>5</sub><sup>+</sup>, -N(R<sub>4</sub>)<sub>2</sub>R<sub>5</sub><sup>+</sup>, -C(=NR<sub>4</sub>)NR<sub>5</sub>R<sub>6</sub>, -C(=X)-C<sub>1</sub>-C<sub>4</sub>-alkylene, wherein the alkylene radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four amino radicals -NR<sub>4</sub>R<sub>5</sub> or a monosaccharide;

R<sub>3</sub> denotes C<sub>5</sub>-C<sub>20</sub>-alkyl, straight chained or branched and optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>5</sub>-C<sub>20</sub>-alkenyl, straight chained or branched having up to five C=C-double bonds and is optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>5</sub>-C<sub>20</sub>-alkynyl, straight chained or branched having up to five C≡C-triple bonds and is optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>6</sub>-C<sub>10</sub>-aryl optionally substituted preferably with C<sub>1</sub>-C<sub>4</sub>-alkyl, F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>7</sub>-C<sub>14</sub>-aralkyl optionally substituted preferably with C<sub>1</sub>-C<sub>4</sub>-alkyl, F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

a C<sub>5</sub>-C<sub>20</sub>-alkyl chain interrupted by up to 10 amino groups -NR<sub>4</sub>- and having optionally an amino-group which is optionally substituted by an amino acid;

R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> denote independently from each other hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

X denotes O or S;

Y denotes C=O or C=S and

Z denotes O, S or -NR<sub>4</sub>-.

In an even more preferred embodiment, the invention relates to transfection particles wherein the cationic precursor molecules according to the general structure described above are substituted as follows:

$R_1$  denotes  $(C_1-C_3\text{-alkylene})\text{-SH}$ , wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

$R_2$  denotes  $-\text{NR}_4\text{R}_5$ ,  $-\text{NHR}_4\text{R}_5^+$ ,  $-\text{N}(\text{R}_4)_2\text{R}_5^+$ ,  $-\text{C}(=\text{NR}_4)\text{NR}_5\text{R}_6$ ,  $-\text{C}(=\text{X})\text{-C}_1\text{-C}_4\text{-alkyl}$ , wherein the alkyl radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four amino radicals  $-\text{NR}_4\text{R}_5$ , or a  $\text{C}_6\text{-monosaccharide}$ ;

$R_3$   $\text{C}_5\text{-C}_{12}\text{-alkyl}$ , straight chained or branched and optionally substituted preferably with F, Cl, Br or  $-\text{NH}_2$ , or a

$\text{C}_5\text{-C}_{15}\text{-alkyl}$  chain interrupted by up to 7 amino groups  $-\text{NR}_4\text{-}$  and having optionally a  $-\text{amino-group}$  which is optionally substituted by the amino acid cysteine;

$R_4$ ,  $R_5$  and  $R_6$  denote independently from each other hydrogen or methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl or tert.-butyl;

X denotes O or S;

Y denotes  $\text{C=O}$  or  $\text{C=S}$  and

Z denotes O, S or  $-\text{NR}_4\text{-}$ .

In a most preferred embodiment, the invention relates to transfection particles wherein the cationic precursor molecules according to the general structure described above are substituted as follows:

$R_1$  denotes  $-\text{CH}_2\text{-SH}$ ;

$R_2$  denotes  $-NH_2$ ,  $-NH_3^+$ ,  $-C(=NH_2^+)NH_2$ ,  $-C(=O)-C_1-C_4$ -alkyl straight chained or branched and optionally substituted with F, Cl, Br or  $-NH_2$

or an ornithine radical or a S-galactosyl radical;

$R_3$  denotes a  $C_6-C_{15}$ -alkyl radical straight chained or branched and optionally substituted preferably with F, Cl, Br or  $-NH_2$ ,

Y denotes  $C=O$ ;

Z denotes O or  $-NH-$ .

Preferred are transfection particles wherein  $R_1$  is  $C_1-C_4$ -alkylene-SH. More preferred are transfection particles wherein  $R_1$  is a methylenethiol.

Preferred are transfection particles wherein  $R_2$  is an amine. More preferred are transfection particles wherein  $R_2$  is a guanidine. Also more preferred are transfection particles wherein  $R_2$  is an ornithine.

Preferred are transfection particles wherein  $R_3$  is a decyl radical.

Preferred are transfection particles wherein Y is a carbonyl.

Also preferred are transfection particles wherein Z is an amine.

Most preferred are transfection particles wherein  $R_1$  is a methylenethiol,  $R_2$  is a guanidine,  $R_3$  is a decane, Y is a carbonyl, Z is an amine, and pharmaceutically acceptable salts thereof.

Especially preferred are transfection particles wherein the cationic molecule is N-decyl-2-guanidinium-cysteine.

Also most preferred are transfection particles wherein  $R_1$  is a methylenethiol,  $R_2$  is an ornithine,  $R_3$  represents a straight chained decyl radical, Y is a carbonyl, Z is an amine, and pharmaceutically acceptable salts thereof.

Also especially preferred are transfection particles wherein the cationic molecule is N-decyl-2-ornithinyl-cysteine.

$C_1$ - $C_6$ -alkyl generally represents a straight-chained or branched hydrocarbon radical having 1 to 6 carbon atoms which may optionally be substituted by one or several halogen atoms - preferably fluorine - which may be identical to one another or different. The following radicals may be mentioned by way of example:

methyl, ethyl, propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methyl-propyl.

The same definition applies accordingly to alkanediyl radicals.

$C_5$ - $C_{30}$ -alkyl refers specifically to a straight-chained or branched hydrocarbon radical having 5 to 30 carbon atoms - for example pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl,

pentadecyl, hexadecyl, dodecadecyl, nonadecyl, eicosyl, henicoyl, docosyl and triacontyl.

Unless otherwise stated, lower alkyl groups having 1 to 5 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert.-butyl, n-pentyl or isopentyl are preferred. The same definition applies to alkandiyl radicals.

Alkenyl in general represents a straight-chained or branched hydrocarbon radical having 3 to 20 carbon atoms and one or more double bonds, preferably one double bond, which may optionally be substituted by one or several halogen atoms - preferably fluorine - which may be identical to another or different. Examples include:

2-propenyl (allyl), 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl.

Alkynyl in general represents a straight chained or branched hydrocarbon radical having 3 to 20 carbon atoms and one or more triple or one or more triple and double bonds.



2-propynyl (propargyl), 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 4-methyl-2-pentynyl, 1-methyl-3-pentynyl, 2-methyl-3-pentynyl, 1-methyl-4-pentynyl, 3-methyl-4-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 1,3-dimethyl-2-butynyl, 1,3-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 2,3-dimethyl-2-butynyl, 2,3-dimethyl-3-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl.

Monosaccharides in the meaning of the present invention represent C<sub>5</sub>- and preferably C<sub>6</sub>- monosaccharides and are for example selected from the following group:

galactose, lactose, glucose, arabinose, fructose, sorbose, xylose, ribose, mannose each of them in their D- or L-form.

Aryl in general represents an aromatic radical having 6 to 10 carbon atoms – also in combinations, it being possible for the aromatic ring to be substituted by one or more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s) – which are identical to one another or different. The preferred aryl group is mentioned – unless otherwise stated – phenyl.

Aralkyl in general represents an aryl radical having 7 to 14 carbon atoms which is bonded via an alkylene chain, it being possible for the aromatic ring to be substituted by one more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s) – which are identical to one another or different. Aralkyl radicals having 1 to 6 carbon atoms in the aliphatic partial structure and 6 to 10 carbon atoms in the

aromatic part are preferred. Preferred aralkyl radicals which may be mentioned - unless otherwise stated - are: benzyl, phenethyl and phenylpropyl.

Alkoxy in general represents an O-alkyl radical wherein alkyl is as defined above. Preferred alkoxy radicals have lower alkyl groups as defined above.

Alkyl or dialkylamino represents an amino radical substituted by one or two alkyl groups which are identical to one another or different. Preferred alkyl or dialkylamino substituents are amino radicals having one or more lower alkyl groups.

In a further embodiment of the invention, the organic cationic precursor molecule is free of a lipophilic residue. Suitable molecules of this type are able to bind to DNA molecules without crosslinking or aggregating them. To fulfill this requirement, they should be small enough to adhere to a single DNA molecule only, without binding to one or more other DNA molecules. In addition, the cationic molecules contain functions that allow them to be covalently linked to other identical or different cationic precursor molecules. The requirements for the functional groups are the same as described for the detergent precursor molecules. Cationic molecules can be tested for their suitability for the present invention by contacting them with DNA and physically examining the obtained complexes for particle size, e.g. by electron microscopy, laser light scattering or atomic force microscopy, before and after covalent linkage. Suitable cationic molecules show no aggregate formation before or after linkage; on the other hand, they must exhibit particle formation after linkage, optionally also before linkage.

Cationic non-lipophilic precursor molecules may be selected from the group comprising molecules with a backbone carrying positively charged groups. The backbone is not critical, it may be any organic molecule that carries a

positive charge, either in the main chain or in a side chain. As an example, the backbone is a peptide, the positive charges are provided by positively charged amino acids, e.g. lysine, arginine, ornithine. Suitable positively charged groups may be the same as defined above for the detergent molecules. Provided that they fulfill the above requirements, the organic cationic precursor molecules may be those that are disclosed in WO 93/07283 for complexing DNA.

The functional groups for covalent linking may be provided by the backbone itself, e.g. if the molecule is a peptide and has cysteine residues, or they may be obtained by linking them to the backbone.

Alkyl or dialkylamino represents an amino radical substituted by one or two alkyl groups which are identical to one another or different. Preferred alkyl or dialkylamino substituents are amino radicals having one or more lower alkyl groups.

In a preferred embodiment transfection particles are characterized in that the cationic precursor molecule is an amine or polyamine.

In a particular preferred embodiment transfection particles are characterized in that the cationic precursor molecule is spermine-N1, N12-bis-cysteineamide (SC<sub>2</sub>).

The aforementioned spermine derivative fulfills all requirements necessary for practicing the invention. Primary and secondary amines provide cationic functions under physiological conditions and two thiol groups allow for dimerization or even oligomerization without crosslinking or aggregating DNA.

The cationic precursor molecule spermine-N1,N12-bis-cysteineamide (SC<sub>2</sub>)

can be prepared from commercially available reagents. In the experiments of the invention the biophysical parameters of transfection particles prepared with SC<sub>2</sub> were determined and it was shown that, as opposed to particles prepared with spermine, they are stable.

The SC<sub>2</sub> molecule is composed of a spermine molecule linked via an amide bond to two cysteine molecules having two free thiol functions. The choice of these two molecules is rather critical. Spermine as well as other polyamines, e.g. putrescine, spermidine, is implicated in maintaining viral DNA in condensed form. Various *in vitro* studies have shown that polyamines compact DNA, and under optimal conditions spermine is capable of condensing DNA into toroid structures of 0.1  $\mu\text{m}$  diameter. Nevertheless these toroids are, although relatively stable over time, sensitive to the saline concentration of the medium. As a matter of fact, at a concentration of 150 mM NaCl (which is the ionic strength of the cell culture medium) spermine decomplexes from the DNA which results in the loss of the toroid structures. Therefore particles of DNA complexed with spermine cannot be utilized for transfection. In order to stabilize the particle structure of the DNA complex, two groups carrying a free thiol function each are grafted at each end of the spermine. Under certain optimized conditions, the SC<sub>2</sub> molecules present in the minor groove of the DNA, which serves as a template, will bind to each other via a disulfide bond, thus providing a backbone for the DNA which is capable of stabilizing the toroid conformation.

The invention is by no means limited to one type of cationic precursor molecules within the transfection particle. The transfection particles may be prepared by covalently linking two or more different cationic precursor molecules. It is obvious that for cationic precursor molecules to be linked to different cationic precursor molecules, they must be complementary and therefore different from the other reaction partner with regard to their

functional groups. Cationic precursor molecules of the invention may also provide a structural variety beside the functional variety for linking other cationic precursor molecules. For specific applications, an expert of the art may find it useful to design transfection particles that satisfy specific requirements by combining structurally different cationic precursor molecules.

Transfection particles have to be stable for the time needed to reach their destination, e.g. target cell or tissue. At the target site, e.g. within a target cell, it is of course necessary to make the nucleic acids of the transfection particles available to that cell.

Material foreign to cells is generally taken up by endocytosis and passes through a series of compartments, inter alia endosomes. Within endosomes, the foreign material is confronted with conditions such as a more acidic pH of about 6 and a great variety of enzymes, especially hydrolases. Transfection particles according to the invention can be taken up by cells and consequently be transferred to endosomal compartments. Within the intracellular compartments, the transfection particles of the invention encounter conditions that cause their disassembly, in particular by cleavage of the dimeric or oligomeric cationic molecules, thereby releasing the nucleic acids for decondensation. Typical break of cationic molecules is caused by the reduction of disulfide bridges; examples for acid labile linkages are hydrazones, Schiff bases (imines), enamines, acetal or ketal functions. It should be noted that the invention is by no means limited to the bonds mentioned above for endosomal cleavage and that an expert of the art is aware of alternative bonds that fulfill the requirements for cationic molecules and are cleavable in the endosomes or other intracellular compartments.

Therefore, in a preferred embodiment of the invention, the transfection

particles are characterized by a linkage between the cationic molecules which is degradable under the conditions of the intracellular compartments.

The novel transfection particles are useful for transfecting cells with nucleic acid molecules *in vitro* as well as *in vivo*. The novel transfection particles are especially useful for transfecting higher eucaryotic cells *in vitro* and *in vivo*.

For efficient delivery of nucleic acid molecules it may be desirable to provide specific cellular targeting functions. This is important for *in vivo* applications to target genes into specific cells, tissues or organs. Transfection efficiency may further be increased by the enhanced endocytotic uptake of the particles into the cells once they are bound to the target cells.

In a further aspect, the invention therefore relates to transfection particles characterized in that they additionally carry one or more functions for specific cellular targeting and/or facilitating endocytosis.

Efficient cellular uptake of the transfection particles can be achieved by ligands that bind to cellular structures on the cell surface and/or trigger internalization of the bound structures.

The cellular targeting functions are, for example, either protein ligands or sugar residues. Examples for ligands are immunoglobulins and fragments or derivatives thereof, lectins, adhesion molecules, cytokines or chemokines, as well as small organic structures, e.g. sugar residues, that recognize specific cellular surface structures and are capable of specific targeting and/or internalization. Well-established examples for targeting functions are transferrin, folic acid, RGD peptide, and a great number of monoclonal and polyclonal antibody. Any ligand that is capable of binding to the target cell and internalizing the particles into the cell may be used,

examples for suitable ligands that may be used in the present invention are given in WO 93/07283.

Therefore, in a preferred embodiment the invention relates to transfection particles characterized in that the targeting and/or endocytotic function is a cellular protein ligand.

In a further embodiment the invention relates to transfection particles according to the invention wherein the targeting and/or endocytotic function is a sugar residue.

In addition to targeting ligands, the particles of the invention may contain a function that enables them to cross cellular membranes, either by membrane fusion, disruption or pore formation (in the following, this function is termed endosomolytic function). In case the cationic precursor molecules are detergents, they have *per se* a membrane destabilizing/endosomolytic function. If the covalent linkage is bioreversible and therefore broken down in the cellular environment, the detergent molecules can exert their endosomolytic function. Alternatively or in addition to the detergent's membrane destabilizing function, this function may be provided by endosomolytic agents. Examples for suitable endosomolytic agents that may be used in the present invention, are disclosed in WO 93/07283. Preferred examples for endosomolytic agents are inactivated adenovirus particles, membrane active peptides (i.e. fusogenic or lytic peptides, examples of which have been disclosed in WO 93/07283 and by Plank et al., 1994; Mechtler and Wagner, 1997; Gottschalk et al., 1996; the DNA binding membrane active peptide disclosed by Wyman et al., 1997; the amphipathic cationic peptide gramicidin disclosed by Legendre and Szoka, 1993 and Legendre and Supersaxo, 1995), and pH sensitive surfactants such as N-alkyl-imidazoles which are disclosed by Wilson et al; 1987 Hughes et al., 1996 and by the references therein.

The targeting and/or endosomolytic functions of the transfection particles of the invention may be covalently linked to few, many or all cationic molecules of the invention and may be identical or different targeting functions within a single transfection particle. The presence of targeting/endosomolytic function, both in terms of type and amount, depends on the specific application, in particular on the cell type to be reached and may be adjusted to the particular requirements. In general, the percentage of cationic molecules that carry such functions may be about 1 to 80 %, preferably about 10 to 50 %.

An example of a precursor molecule with a targeting function that is capable of binding covalently to precursor molecules of the cationic molecules of the invention is a lipophilic galactosyl cysteine (Remy et al., 1995) (see example 5). Although this lipophilic galactosyl cysteine does not provide *per se* the functionality required for complexing nucleic acid molecules it is capable of covalently binding to cationic precursor molecules to provide cationic molecules (heterodimers) that are part of the transfection particles of the invention. Galactosyl residues are known to be targeting functions specifically recognized by liver cells.

The targeting/endosomolytic function may also be present in the form of a conjugate, wherein it is attached to a DNA binding molecule that is present in addition to the oligomerisable precursor molecule. This molecule may be a oligocation like oligolysine or a polymer like polyethyleneimine without dimerizable functions. These targeting/endosomolytic conjugates may be added to the other complex partners of the transfection particle before or during complex formation.



The ligand/endosomolytic function may be incorporated into the transfection particles in the following ways:

- a) providing the cationic precursor molecules and/or non-oligomerizable small DNA binding molecules that are equipped with a targeting/endosomolytic function before or during complex formation;
- b) attaching the targeting/endosomolytic function to the cationic precursor molecules and/or or non-oligomerizable small DNA binding molecules after complex formation before or during covalently linking the precursor molecules;
- c) attaching the targeting/endosomolytic function after covalently linking the precursor molecules.

In the case of b) and c) the precursor molecules or non-oligomerizable molecules are equipped with a reactive group that allows for binding the targeting/endosomolytic function. Reactive group means chemically reactive, e.g. activated esters, disulfides, or allowing for biochemical interaction, e.g. streptavidin/biotin binding (in this case the molecule is equipped with streptavidin or biotin to react). The reactive group must be selected such that it does not interfere with the process of covalently linking the precursor molecules.

The embodiment a) has the advantage that the molecules carrying the targeting/endosomolytic function can be prepared in advance in purified form in larger amounts and are readily available as well-defined reagents. This embodiment is in particular applied for the endosomolytic function when it is desirable to have this function within the transfection particle.

Embodiments b) and c) are preferred for large ligands, like protein targeting

ligands, or endosomolytic agents like adenoviruses because these ligands/agents may interfere with condensation of DNA complexes to small particles. It is an advantage of these embodiments that they guarantee that the function is located at the surface of the particle. Embodiment c) is additionally advantageous if the ligand is sensitive to the conditions used for condensing and/or covalently linking of precursor molecules.

In a further embodiment, the present invention is directed to transfection particles in which the targeting function is provided by a sugar residue.

In a preferred embodiment, the sugar is galactose.

In another preferred embodiment, the sugar is mannose.

In a further embodiment, the endosomolytic function is provided by a fusogenic peptide.

Methods for attaching agents providing targeting/endosomolytic functions, e.g. small organic molecules such as sugars or larger structures such as proteins or entire viruses, to the cationic molecules are available to the expert.

Binding by chemical methods can be effected in the manner which is already known for the coupling of peptides and, if necessary the individual components may be provided with linker substances before the coupling reaction (this measure is necessary if there is no functional group available which is suitable for the coupling, e.g. a mercapto or alcohol group). The linker substances are bifunctional compounds which are reacted first with functional groups of the individual components, after which the modified individual components are coupled.

Coupling may be carried out by means of

- a) disulphide bridges, which can be cleaved again under reducing conditions (e.g. when using succinimidyl-pyridyldithiopropionate);
- b) compounds which are substantially stable under biological conditions (e.g. thioethers by reacting maleimido linkers with sulfhydryl groups of the linker bound to the second component);
- c) bridges which are unstable under biological conditions, e.g. ester bonds, or acetal or ketal bonds which are unstable under slightly acidic conditions;
- d) reactive groups like isothiocyanate, activated esters;
- e) reactive coupling of aldehydes with amino groups.

In a preferred embodiment, the nucleic acid of the transfection particles is DNA.

The DNA may be linear or circular, single-stranded or double stranded. Concerning the size of the DNA, the invention allows for a wide range between small oligonucleotides containing approximately 20 nucleotides and very large molecules like artificial chromosomes of ca. 100 to 2000 kb.

In a preferred embodiment, the particles are monomolecular with respect to the DNA, which means that they contain a single DNA molecule. This embodiment is particularly useful for the delivery of DNA *in vivo* where it is desirable to apply small particles in order to overcome the size limitations of the physiological barriers.

Furthermore, the availability of monomolecular discrete stable particles is advantageous for the delivery of large DNA molecules *in vitro* and *in vivo* because such particles are more readily taken up by cells than large aggregates.

The particles may, however, contain more than one DNA molecules, in particular when smaller DNA molecules like oligonucleotides are applied.

The particles of the invention are generally spherical in structure, their diameter may vary from approximately 25 nm (in case of plasmid DNA) to several hundred nm. It has been found that the volume of the formed particles is directly proportional to the length of DNA. This strongly suggests that the condensation of the DNA molecules is monomolecular.

In a further aspect, the invention comprises the use of cationic molecules and/or cationic precursor molecules for preparing novel nucleotide transfection particles.

In a further aspect, the invention comprises a method for preparing transfection particles, characterized in that cationic precursor molecules are added to nucleic acid molecules in a suitable buffer, allowed to form complexes with the nucleic acid and allowed to covalently link to identical or different cationic precursor molecules on the nucleic acid template.

In a first step of the method, a DNA solution which contains one type of DNA molecules or a mixture of different molecules in a buffer is mixed with a solution of precursor molecules, optionally with different precursor molecule solutions.

Starting from the DNA concentration that is desired in the final transfection

formulation and a given ratio of positive and negative charges, which depends on the specific application, the amount and the physical characteristics (solubility, c.m.c., etc.) of the precursor molecules are determined. Specific applications may be defined by the administration route, e.g. the systemic or the intravenous route, for which the transfection particles should not be positively charged in order to avoid undesired reactions with blood components, or by the cells to be targeted, which may require considering the preference for specific binding charged particles. For selecting a suitable detergent as a precursor molecule, its critical micelle (c.m.c.) concentration, which is known for a given detergent or may be determined by means of a Langmuir balance, is important. For the concept of the invention, optimal results are obtained if the concentration of the detergent is below the c.m.c.

The components are incubated under conditions that allow for complex formation; usually the complexes can form at room temperature during a short period of time, i.e. between several minutes and few hours. After mixing the complex partners, the precursor molecules are covalently linked, which may, dependent on the rate of complex formation, occur immediately after mixing or after the required longer period of time. Depending on the reactive groups available for linkage, linkage may occur spontaneously upon contact of the precursor molecules when bound to DNA. Alternatively, linkage may need to be mediated by an additional agent, such as oxygen. The conditions need to be such that they do not affect the DNA molecule, therefore most precursor molecules that are preferably used in the present invention are dimerizable or oligomerizable simply by air. The suitable reaction conditions and the time course of the reaction steps can be determined by carrying out routine experiments in which the parameters are varied and the physical characteristics of the (intermediate) reaction products (complexes and compacted particles) are monitored, e.g. particle size measurement by laser light scattering.

In case targeting/endosomolytic functions are present or are to be provided on the precursor molecules or on additional, non-dimerizable cationic molecules, the method, e.g. in terms of incubation period for complex formation or introducing additional steps for modification of the cationic molecules, may be adapted.

Suitable buffers for preparing the novel transfection particles are any buffers that allow complex formation and/or are compatible with the conditions for covalent linkage between individual cationic precursor molecules and for attaching the optional targeting/endosomolytic function. Other parameters such as the optimum pH value, the incubation time, the temperature, and the concentrations of nucleic acids and cationic precursor molecules and optionally molecules for targeting and/or endocytosis depend on each individual embodiment. These parameters may be optimized in routine serial experiments without undue burden for any the expert because the parameters are limited, for example to aqueous systems and to moderate conditions that do not alter the nucleic acid molecules. Furthermore, the Examples describe such parameters which may be easily modified. For example, suitable parameters for oxidizing cysteine precursor molecules in the presence of nucleic acid molecules that comprise a decane hydrophilic function and a guanidine cationic function to provide disulfide bridges are a stock buffer solution of 15 mM TrisHCl, pH 8.4, saturated with oxygen from three vacuum/oxygen atmosphere cycles, 90  $\mu$ M (final concentration) cationic precursor molecules added before the addition of 60  $\mu$ M (final concentration) plasmid DNA.

A preferred use for the novel transfection particles of the invention is *in vivo* delivery of nucleic acid into mammalian cells for therapeutic applications.

In this case the nucleic acid is therapeutically active, e.g. an antisense

oligonucleotide or a plasmid encoding a therapeutically active protein. There are no limitations in terms of DNA sequence, any sequence that is useful in therapy, e.g. somatic gene therapy or immunotherapy, may be used. Non-limiting examples are given in WO 93/07283.

Therefore, in a further aspect, the invention relates to pharmaceutical compositions for gene delivery comprising transfection particles containing a therapeutically effective amount of a nucleic acid.

Such pharmaceutical compositions may comprise transfection particles prepared freshly before administration, or off-the-shelf preparations which may be stored as a cooled liquid, in frozen form or as a lyophilisate, and which may contain additional additives such as stabilizers, cryoprotectives, etc. Suitable additives are known in the art; reference is made to Remington's Pharmaceutical Sciences, 1980, for methods of formulating pharmaceutical compositions. In the experiments of the present invention, it has been shown that compositions containing the transfection particles of the invention are efficient for intradermal gene delivery.

In a preferred embodiment, the pharmaceutical composition is useful for intradermal application.

Apart from *in vivo* DNA delivery, the particles of the invention are particularly useful for introducing large DNA molecules, e.g. artificial chromosomes into mammalian cells, which may be important for regulated long-term gene expression.

For *in vivo* and *in vitro* transfection a kit of parts for the preparation of transfection particles with the desired nucleic acid molecules can provide great convenience. Such a kit of parts may contain, for example, one or more types of cationic precursor molecules that may be used in different

combinations to optimize their properties, one or more molecules for cell specific targeting/endosomolytic function, suitable buffers, and other reagents or mechanical devices that are useful for preparing, purifying or applying the novel transfection particles *in vitro* and *in vivo*.

In the following, the invention is exemplified for the cationic precursor molecule N-decyl-2-guanidinium-cysteine:

The detergent molecule was designed de novo (Example 1). Due to the preference for mild chemistry and the use of endogeneous-like compounds thiol was chosen as a dimerizable function, and cysteine was chosen as the non-toxic recipient backbone for constructing the polyfunctional molecule. It can be expected that once inside the endosomal compartment both lipophilic cysteine ester or amide vectors will be enzymatically cleaved back to cysteine and an aliphatic alcohol or amine with concomitant DNA decondensation and possible endosome lysis.

Clean monomolecular DNA collapse is generally expected only for detergent concentrations below the critical micelle concentration (c.m.c.). Several n-alkyl esters of cysteine were synthesized by DMAP-catalyzed dicyclohexylcarbodiimide (DCC) dehydration and their c.m.c.'s were determined with a Langmuir balance (20 mM MES buffer, pH 6), providing the following results (n-alkyl chain length / c.m.c.): dodecane / 15  $\mu$ M; undecane / 80  $\mu$ M; decane / 320  $\mu$ M; octane / > 2000  $\mu$ M. Typical working plasmid concentrations for gene delivery experiments being in the 50  $\mu$ M range, the decane chain is a safe choice. The weakly basic nature of the cysteine ester primary amine function ( $pK_a = 6.8$ ) is insufficient for simultaneous DNA binding (which requires a protonated detergent) and reasonable thiol oxidation rates in slightly basic medium. The amine function was therefore converted into a highly basic guanidine which is known to interact strongly with DNA ( $C_{10}C^{G+}$ , Fig. 2).



Oxidative detergent dimerization was expected to be prone to a template effect of DNA (Fig. 1). Fast intra-complex reaction is a key aspect to formation of small and stable particles since extensive detergent dimerization into lipid prior to DNA binding would bring the system back to a classical cationic lipid/DNA complex formation/aggregation process. Enhanced air oxidation rate was indeed observed in the presence of DNA (Fig. 3).

Below the c.m.c., the major attractive force is that of anionic DNA towards isolated cationic amphiphile molecules. Prior to oxidation, complexes should therefore be close to electroneutrality even when the detergent is slightly in excess. Therefore plasmid DNA (60  $\mu\text{M}$  in 15 mM TrisHCl pH 8.4) was mixed with  $\text{C}_{10}\text{C}^{\text{G}^+}$  (to 90  $\mu\text{M}$ ) and left in aerobic conditions for 24 h. During the instantaneous complex formation step, the typical UV absorption spectrum of DNA centered at 260 nm was increased by 15%; no further change (once corrected for disulfide absorption) and no turbidity was observed during oxidation. The CD spectrum of the complexes was typical of B-DNA, ruling out the occurrence of a liquid crystalline Y-DNA phase in the complexes. It remained time-independent over a period of 24 h. The most stringent test of stability, however, was that performed in physiologically relevant ionic concentrations, where cationic lipid/DNA complexes are known to aggregate<sup>3, 9</sup>. Remarkably, the UV spectrum of  $(\text{C}_{10}\text{C}^{\text{G}^+})_2/\text{DNA}$  complexes remained unchanged after 3 days in 150 mM NaCl. Spectroscopy thus gave indirect evidence for the formation of small and stable amphiphile/DNA complexes.

Transmission electron microscopy (TEM) of an unfiltered solution of these complexes displayed a surprisingly homogeneous population of nearly spherical objects (71% monomers,  $n=109$ ) with a few larger structures (Fig. 4a). Moreover, the larger structures were clearly dimers (Fig. 4b, d) or

oligomers which may have arisen incidentally and which displayed no tendency to merge into more intimately fused aggregates as cationic lipids do<sup>3</sup>. Raising stepwise the detergent concentrations above the c.m.c. of  $C_{10}C^{G+}$  progressively led to less clearcut UV and TEM results due to time-dependent aggregation (data not shown), in agreement with the hypotheses underlying the concept. At the highest magnification (Fig. 4c) the particle size was measured to be  $23 \pm 4$  nm. A rough calculation using typical DNA and amphiphile molecular dimensions led to a sphere of 28 nm diameter when adding the volumes of a 5.5 Kbp plasmid to that of 5 500 lipid molecules. TEM thus provides strong evidence for monomolecular DNA collapse.

In a series of experiments, the reversibility of complex formation as well as the stability of complexed DNA towards degradation were assessed by electrophoresis (Fig. 5). While  $C_{10}C^{G+}$  was unable to retard DNA migration, except for concentrations well above the c.m.c. where presumably precipitation occurs (not shown), the oxidized  $(C_{10}C^{G+})_2$ /DNA particles did not migrate and were stable during electrophoresis (Fig. 5, lane 2). Yet the cationic lipid/DNA particles could be destroyed either with excess sodium dodecyl sulfate detergent (SDS, lane 3) or by converting the lipid back to the original  $C_{10}C^{G+}$  detergent with excess reducing dithiothreitol (DTT, lane 4). Serum nucleases present in cell culture medium rapidly degrade supercoiled plasmid DNA (lanes 1 and 8) into a smear of fragments with many nicks (lane 5). The lipid/DNA particles, however, are physically stable in this medium (lane 6) and protect to a large extent the nucleic acid from degradation, as the plasmid is essentially converted into a slower migrating circular relaxed form (revealed after SDS treatment, lane 7).

Initial experiments using cationic particles formed with a 3-fold excess detergent led to reporter gene expression in BNL CL 2 murine hepatocytes, confirming that, once in the cell, the fate of the complexes was that of a

non-viral vector. Further experiments demonstrated *in vitro* expression using DNA complexes coated with polycation conjugates or with polycation-ligand conjugates or with particles containing inactivated adenovirus. Furthermore, *in vivo* gene expression after intradermal complex delivery could be demonstrated.

#### Brief description of the figures

- Fig. 1: Schematic representation of cationic detergent-induced monomolecular collapse of plasmid DNA
- Fig. 2: Synthesis of a lipophilic guanidyl-cysteine amide detergent
- Fig. 3: Oxidation rate of cysteine detergent  $C_{10}C^{G+}$  into cystine lipid  $(C_{10}C^{G+})_2$  occurs faster in the presence of template DNA
- Fig. 4: Transmission electron microscopy of an unfiltered solution of  $(C_{10}C^{G+})_2$  cationic lipid / DNA particles
- Fig. 5: Physical and chemical stability of the  $(C_{10}C^{G+})_2$  / DNA complexes (agarose gel electrophoresis)
- Fig. 6: Nanosizing DNA particles condensed with  $C_{10}C^{G+}$  Measurement of particle size  
 A: Phage lambda DNA  
 B: Phage T4 DNA  
 C: CMVL DNA

**Fig. 7A,B: Nanosizing DNA particles condensed with  $C_{10}C^{G+}$  Proof for monomolecular DNA condensation**

**Fig. 8: Transfection of lipophilic guanidyl cysteine amide ( $C_{10}C^{G+}$ )/DNA complexes into the cell line BNL CL.2**

**Fig. 9: Synthesis of a lipophilic alcohol cysteine ester detergent**

**Fig. 10: Determination of the critical micelle concentration (c.m.c.) of the lipophilic alcohol cysteine ester detergents with and without DNA. c.m.c. of a detergent with C8, C10, C11 and C12 cysteine.**

**Fig. 11: Determination of the critical micelle concentration (c.m.c.) of the lipophilic alcohol cysteine ester detergents with and without DNA**  
**A: c.m.c. of C10 cysteine detergent with and without DNA**  
**B: c.m.c. of C11 cysteine detergent with and without DNA)**

**Fig. 12: Oxydation of C10 cysteine detergent with and without DNA**

**Fig. 13: Synthesis of a lipophilic alcohol guanidyl-cysteine ester detergent**

**Fig. 14: Synthesis of a lipophilic ornithyl-cysteine amide detergent**

**Fig. 15: Synthesis of a lipophilic alcohol galactosyl-cysteine ester detergent**

**Fig. 16: UV spectroscopy of spermine-N1,N12-bis-cysteineamide or spermine particles**

**Fig. 17: Agarose gel electrophoresis. Stability of particles formed either with spermine or with spermine-N1,N12-bis-cysteineamide**

- Fig. 18: Size measurement of particles resulting from the interaction of a  $(C_{10}C^{G+})_2$ /DNA complex with different amounts of PEI 25KDa
- Fig. 19: Size measurement of  $(C_{10}C^{G+})_2$ /PEI 25KDa-Gal4/DNA complexes
- Fig. 20: Transfection of SKOV3 cells with  $C_{10}C^{G+}$ /DNA/PEI 25KDa complexes
- Fig. 21: Transfection of BNL CL.2 cells with  $C_{10}C^{G+}$ /DNA/PEI 25KDa and  $C_{10}C^{G+}$ /DNA/PEI 25KDa-Gal4 complexes
- Fig. 22: Coating of  $(C_{10}C^{G+})_2$ /DNA complexes with a polycation linked to a protein
- Fig. 23: Measurement of the zeta potential of transferrin-polylysine-coated  $(C_{10}C^{G+})_2$ /DNA particles
- Fig. 24: Transfection of K562 cells: effect of transferrin-polylysine on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes
- Fig. 25: Transfection of B16F10 cells: effect of transferrin-polylysine on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes
- Fig. 26: Transfection of B16F10 cells: effect of inactivated adenovirus particles on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes
- Fig. 27: Intradermal delivery of  $(C_{10}C^{G+})_2$ /DNA complexes *in vivo*
- Fig. 28: Intradermal delivery of  $(C_{10}C^{G+})_2$ /DNA complexes *in vivo*

Fig. 29: Intradermal delivery of  $C_{10}C^{G+}$ /pCMVL/MannITC-PEI(25KDa) complexes *in vivo*

Fig. 30: Transfection of BNL CL.2 cells with  $(C_{12}CO)_2$ /DNA complexes

### Abbreviations

Ac =  $CH_3 - C(O)$

DCC = dicyclohexylcarbodiimide

DMAP = dimethylaminopyridine

DCU = dicyclohexylurea

DDT = dithiothreitol

DMEM = Dulbeccos Modified Minimum Essential Medium

EDC = N-(3-Dimethylaminopropyl)-N-ethyl-carbodiimide hydrochloride

Et =  $C_2H_5$

Ether = diethylether

HEPES = hydroxyethylpiperazino ethane sulfonic acid

Me = Methyl

MES = Morpholinoethane sulfonic acid

MS = mass spectrometry

MES = PEI = polyethylenimine

BocON = 2-tert-butoxycarbonyl-oxyimino)-2-phenylacetonitrile

$\mu M$  bp = micromolar concentration of DNA calculated per base pair  
(MW = 660)

$C_{10}-C^{G+}$  = Lipophilic guanidyl-cysteine amide

TA = Tris-acetate

THF = tetrahydrofuran

TLC = thin layer chromatography


## Example 1

### a) Synthesis of a lipophilic guanidyl-cysteine amide detergent

The Synthesis of the lipophilic compound was carried out according to the scheme as depicted in Fig. 2.

#### Step 1

##### Manufacture of N-*tert*-butoxycarbonyl-pyrazole-1-carboxamide



To a solution of di-*tert*-butyl dicarbonate (7.43 g, 33 mmol) in 100 ml dichloromethane 11.3 ml of N,N-diisopropylethylamine (66 mmol) and 4.40 g of 1H-pyrazole-1-carboxamide hydrochloride (30 mmol) were added. The solution was agitated for 3 h at room temperature and then evaporated to dryness. The obtained white solid was dissolved in 200 ml ethylacetate, the organic phase was washed with 5 % (w/w) sodium hydrogen carbonate, dried over magnesium sulfate and finally evaporated to dryness. The residue was dissolved in boiling hexane. The solution was allowed to stand at room temperature over night and then at 4°C for 24 h. The crystals thus formed were recovered by filtration and washed in cold hexane (0°C). After drying, 5.28 g of white crystals were obtained (25 mmol yield=84 %).

$C_9H_{14}N_4O_2$ ; 210,24 g/mol

TLC : R<sub>f</sub> (20% AcOEt / Hexane) = 0,3.


TLC on reverse phase:  $R_f$  (60%  $\text{CH}_3\text{CN}$  / 30%  $\text{H}_2\text{O}$  / 10%  $\text{MeOH}$ ) = 0,5.

$\text{NMR}^1\text{H}$  ( $\text{CDCl}_3$ );  $\delta$  ppm : 1,56 (s, 9H,  $\text{C}(\text{CH}_3)_3$ ); 6,41 (dd,  $J_1=3$  Hz,  $J_2=1,5$  Hz, 1H,  $\text{CH}-\text{CH}=\text{CH}$ ); 7,50-7,70 (brs, 1H,  $=\text{NH}$ ); 7,69 (d,  $J=1,1$  Hz, 1H,  $\text{N}=\text{CH}$ ); 8,46 (d,  $J=3$  Hz, 1H,  $\text{N}-\text{CH}$ ); 9,01-9,20 (brs, 1H,  $\text{NHBoc}$ ). (In this and in the other NMR spectra, the hydrogen atoms assigned to the signal are in bold print.)

MS (FAB+),  $m/z$  : 211,1 [ $\text{MH}^+$ ]; 155,0 [ $\text{MH}^+ - t\text{-Butyl}$ ].

## Step 2

Manufacture of N,N'-bis-*tert*-butoxycarbonyl-pyrazole-1-carboxamidine



To a suspension of sodium hydride (1.60 g, 40 mmol) in 70 ml tetrahydrofuran at  $0^\circ\text{C}$  2.10 g N-*tert*-butoxycarbonyl-pyrazole-1-carboxamidine (10 mmol) were added. The suspension was intensely agitated for 1 h at  $0^\circ\text{C}$ . Then 4.5 g di-*tert*-butyl dicarbonate (20 mmol) were added and placed at room temperature and then gradually heated to the reflux. After one night under reflux the reaction medium was cooled to  $0^\circ\text{C}$ ; 2.3 ml acetic acid were added and the solution was agitated during 15 min. The organic phase was washed with 60 ml 5 % (w/w) sodium hydrogen carbonate, 60 ml of a saturated NaCl solution, dried over magnesium sulfate and then evaporated to dryness. The obtained residue was purified by silica chromatography (gradient 5 to 15 % ethylacetate in hexane) to obtain 2.48 g of a white solid (8.0 mmol, yield=80 %).

$\text{C}_{14}\text{H}_{22}\text{N}_4\text{O}_4$ ; 310,36 g/mol



TLC : R<sub>f</sub> (20% AcOEt / Hexane) = 0,3.


TLC on reverse phase: R<sub>f</sub> (60% CH<sub>3</sub>CN / 30% H<sub>2</sub>O / 10% MeOH) = 0,4.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  ppm : 1,52 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,58 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 6,43-6,46 (m, 1H, CH-CH=CH); 7,64-7,66 (m, 1H, N=CH); 8,33 (d, J=3 Hz, 1H, N-CH); 8,93 (brs, 1H, NHBoc).

MS (FAB+), m/z : 311,1 [MH<sup>+</sup>]; 255,0 [MH<sup>+</sup> - *t*-Butyl]; 211,0 [MH<sup>+</sup> - Boc]; 199,0 [MH<sup>+</sup> - 2*t*-Butyl]; 155,0 [MH<sup>+</sup> - Boc - *t*-Butyl].

### Step 3

#### Manufacture of N,S-bis-*tert*-butoxycarbonylcysteine-decylamide



To a solution of N,S-bis-*tert*-butoxycarbonylcysteine (1 g; 3.11 mmol) in 6 ml dichloromethane and 200  $\mu$ l tetrahydrofurane 430 mg N-hydroxysuccinimide (3.73 mmol) were added. The reaction mixture was cooled to 0°C and 713 mg N,N'-dicyclohexylcarbodiimide (3.42 mmol) were added. After 2 h of reaction at 0°C, 680  $\mu$ l decylamine (3.42 mmol) were introduced and the solution was agitated for 6 h at ambient temperature. Then the reaction medium was filtered, evaporated to dryness and then taken up in 200 ml ethylacetate. The organic phase was washed in subsequent steps with 100 ml 5 % (w/w) sodium hydrogen carbonate, 100 ml water, 100 ml citric acid 0.5 M, 100 ml water, then dried over magnesium sulfate and then evaporated to dryness. The obtained residue was

purified by silica chromatography (gradient 1 to 3 % methanol in dichloromethane) to obtain 1.27 g of a translucent oil (2.75 mmol, yield=88 %).

$C_{23}H_{44}N_2O_5S$ ; 460,68 g/mol


TLC :  $R_f$  (5% MeOH / 1% AcOH /  $CH_2Cl_2$ ) = 0,6.

NMR<sup>1</sup> H ( $CDCl_3$ );  $\delta$  ppm: 0,89 (t,  $J=7$  Hz, 3H,  $CH_3$ ); 1,21-1,38 (m, 14H,  $CH_3-(CH_2)_7-CH_2CH_2NH$ ); 1,45 (s, 9H,  $NH-C(CH_3)_3$ ); 1,51 (s, 9H,  $S-C(CH_3)_3$ ); 1,42-1,58 (m, 2H,  $CH_2-CH_2NH$ ), 3,08-3,32 (m, 4H,  $CH_2-S$ ,  $CH_2-NHCO$ ); 4,27 (dd,  $J_1=13$  Hz,  $J_2=8$  Hz, 1H,  $CH-CONH$ ); 5,35-5,43 (brs, 1H,  $NHBoc$ ); 6,28-6,37 (brs, 1H,  $NHCOCH$ ).

MS (FAB+),  $m/z$  : 461,3 [ $MH^+$ ]; 405,3 [ $MH^+ - t\text{-Butyl}$ ]; 361,3 [ $MH^+ - Boc$ ]; 349,2 [ $MH^+ - 2 t\text{-Butyl}$ ]; 305,2 [ $MH^+ - t\text{-Butyl} - Boc$ ]; 261,2 [ $MH^+ - 2Boc$ ].

#### Step 4

Manufacture of *S*-*tert*-butoxycarbonylcysteine-decylamide



461 mg N,S-bis-*tert*-butoxycarbonyl-L-cysteine-decylamide (1 mmol) were dissolved in 3 ml 2N HCl/AcOEt at 0°C and agitated for 1 h. The solution was evaporated to dryness and then taken up in 100 ml ethylacetate. The organic phase was washed twice with 5 % (w/w) sodium hydrogen carbonate, dried over

magnesium sulfate and then evaporated to dryness. The obtained oil was purified by silica chromatography (gradient 0 to 3 % methanol in dichloromethane) to obtain 233 mg of a translucent oil (0.65 mmol, yield=65 %).

$C_{18}H_{36}N_2O_3S$ ; 360,56 g/mol


TLC :  $R_f$  (10% MeOH /  $CH_2Cl_2$ ) = 0,7.

NMR<sup>1</sup> H ( $CDCl_3$ );  $\delta$  ppm: 0,89 (t,  $J=6$  Hz, 3H,  $CH_3$ ); 1,10-1,40 (m, 14H,  $CH_3-(CH_2)_7-CH_2CH_2NH$ ); 1,41-1,58 (m, 2H,  $CH_2-CH_2NH$ ); 1,50 (s, 9H,  $S-C(CH_3)_3$ ); 1,62 (brs, 2H,  $NH_2$ ); 3,06 (dd,  $J_1=14$  Hz,  $J_2=8$  Hz, 1H,  $CH-S$ ); 3,24 (dt,  $J_1=7$  Hz,  $J_2=7$  Hz, 2H,  $CH_2-NHCO$ ); 3,37 (dd,  $J_1=14$  Hz,  $J_2=4$  Hz, 1H,  $CH-S$ ); 3,55 (dd,  $J_1=8$  Hz,  $J_2=4$  Hz, 1H,  $CH-CONH$ ); 7,3-7,4 (brs, 1H,  $NH$ ).

MS (FAB+),  $m/z$  : 361,2 [ $MH^+$ ]; 305,1 [ $MH^+ - \text{tert-Butyl}$ ]; 261,1 [ $MH^+ - \text{Boc}$ ].

## Step 5

Manufacture of N,N'-bis-*tert*-butoxycarbonyl-guanidiny-*S-tert*-butoxycarbonylcysteine-decylamide



N,N'-bis-*tert*-butoxycarbonyl-pyrazole-1-carboxamidine (178 mg; 0.572 mmol) was added to a solution of *S-tert*-butoxycarbonylcysteine-decylamide (227 mg;

0.630 mmol) in 3 ml acetonitrile. The reaction mixture was stirred for 2 days at room temperature and taken to dryness. The residue was purified by silicagel chromatography (10-15% ethyl acetate in hexane), leading to a white solid (281 mg; 0.47 mmol, 81%).

$C_{29}H_{54}N_4O_7S$ ; 602,84 g/mol


TLC:  $R_f$  (20% AcOEt / Hexane) = 0,6.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  ppm: 0,9 (t,  $J=6$  Hz, 3H, CH<sub>3</sub>); 1,18-1,40 (m, 14H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH<sub>2</sub>CH<sub>2</sub>NH); 1,45-1,65 (m, 29H, 3 X -C(CH<sub>3</sub>)<sub>3</sub>, CH<sub>2</sub>-CH<sub>2</sub>NH); 3,17-3,35 (m, 4H, CH<sub>2</sub>-S, CH<sub>2</sub>-NHCO); 4,8 (dd,  $J_1=11$  Hz,  $J_2=6$  Hz, 1H, CH-CONH); 6,98-7,07 (m, 1H, CH<sub>2</sub>CH<sub>2</sub>NH); 8,81 (d,  $J=7$  Hz, NH-Boc); 11,36 (sl, 1H, NH-CN(NH)).

MS (FAB+),  $m/z$  : 603.3 [MH<sup>+</sup>]; 547.2 [MH<sup>+</sup> - *t*-Butyl]; 503.3 [MH<sup>+</sup> - Boc]; 447.2 [MH<sup>+</sup> - *t*-Butyl - Boc]; 403.2 [MH<sup>+</sup> - 2Boc]; 347.1 [MH<sup>+</sup> - *t*-Butyl - 2Boc]; 303.2 [MH<sup>+</sup> - 3Boc].

## Step 6

### a) Manufacture of Guanidyl-cysteine-decylamide (C<sub>10</sub>C<sup>G+</sup>)



N,N'-bis-*tert*-butoxycarbonyl-guanidinyI-S-*tert*-butoxycarbonylcysteine-decylamide (60 mg; 0.1 mmol) was dissolved into 1 ml trifluoroacetic acid and stirred under argon atmosphere for 2 h at room temperature. The mixture was taken to dryness and the resulting colorless oil was dissolved into 1 ml perdeuteroethanol. The resulting 0.1 M stock solution was kept under argon

atmosphere at  $-80^{\circ}\text{C}$ . The thiol content was determined with Elmann's reagent following the method of Riddles et al. (87%).

$\text{C}_{14}\text{H}_{30}\text{N}_4\text{OS}$ ; 302,48 g/mol

$\text{NMR}^1\text{H}$  ( $\text{CD}_3\text{CD}_2\text{OD}$ );  $\delta$  ppm: 0,90 (t,  $J=6$  Hz, 3H,  $\text{CH}_3$ ); 1,27-1,42 (m, 14H,  $\text{CH}_3-(\text{CH}_2)_7-\text{CH}_2\text{CH}_2\text{NH}$ ); 1,50-1,61 (m, 2H,  $\text{CH}_2-\text{CH}_2\text{NH}$ ); 2,90-3,35 (m, 4H,  $\text{CH}_2-\text{S}$ ,  $\text{CH}_2-\text{NHCO}$ ); 4,32-4,40 (m, 1H,  $\text{CH}-\text{CONH}$ ).

b) Oxidation rate of cysteine detergent  $\text{C}_{10}\text{C}^{\text{G}+}$  into cystine lipid  $(\text{C}_{10}\text{C}^{\text{G}+})_2$  occurs faster in the presence of template DNA. The stock buffer solution (TrisHCl 15 mM pH 8.4) was saturated with oxygen by three vacuum/oxygen atmosphere cycles.  $\text{C}_{10}\text{C}^{\text{G}+}$  was injected from a concentrated stock solution to a final concentration of 90  $\mu\text{M}$ . For each time point, a 0.5 ml aliquot was removed and mixed with 0.5 ml 2XEllman's reagent. The remaining free thiol was quantitated spectrophotometrically according to Riddles et al. (1979). For the template experiment, pCMVL plasmid DNA (prepared as described in WO 93/07283 was added to a final concentration of 60  $\mu\text{M}$  before addition of the detergent. The results of the experiment are shown in Fig. 3.

c) Transmission electron microscopy (Fig. 4)

Transmission electron microscopy of an unfiltered solution of  $(\text{C}_{10}\text{C}^{\text{G}+})_2$  cationic lipid / DNA particles showing (a) a very homogeneous population (b) of spheres (c, d) with a diameter of ca. 23 nm; scale bar corresponds to 100 nm for all pictures. Sample solution was prepared by adding the detergent (90  $\mu\text{M}$  final concentration) to a 60  $\mu\text{M}$  pCMVL DNA solution in HEPES buffer (15 mM, pH 7.4) and leaving the solution in aerobic condition overnight. Carbon films were prepared by sublimation on freshly cleaved mica and recovered by flotation on Cu/Rh grids (300 mesh, Touzard&Matignon, Courtaboeuf, France). After overnight drying; grids were kept on a blotting paper in a Petri dish. Immediately

before sample addition, grids were glow-discharged (110 mV, 25 s). A drop (5  $\mu$ l) of sample solution was left on the grid for 1 min. Complexes were negatively stained with 30  $\mu$ l aqueous uranylacetate (1% w/w) for 20 s, and excess liquid was removed with blotting paper. Observations were performed at 80 kV with a Philips EM 410 transmission electron microscope. Similar results were obtained with complexes observed in 0.15 M NaCl. (Fig. 4).

d) Physical and chemical stability of the  $(C_{10}C^{G+})_2$  / DNA complexes (Fig. 5).

1% agarose gel electrophoresis (90 min at 8 V/cm in 40 mM Tris-acetate buffer pH 8) of 20  $\mu$ l samples containing 0.4  $\mu$ g (lanes 1-4) or 0.2  $\mu$ g (lanes 5-8) pCMV-luc plasmid DNA. Complexes were made by addition of a 100-fold concentrated  $C_{10}C^{G+}$  detergent solution (90  $\mu$ M final concentration) to a solution of plasmid (60  $\mu$ M) in HEPES buffer (15 mM, pH 7.4). The solution was gently mixed once and left to oxydize for 24 h. Lane 1: 60  $\mu$ M plasmid DNA. Lane 2: 60  $\mu$ M oxydized  $(C_{10}C^{G+})_2$ /DNA complexes. Lane 3: as lane 2 in 3 mM final sodium dodecylsulfate before loading. Lane 4: as lane 2 in 6 mM dithiothreitol before loading. Lane 5: 60  $\mu$ M plasmid incubated for 1 h at 37 °C with an equivalent volume of DMEM cell culture medium containing 10% serum. Lane 6: 60  $\mu$ M oxydized  $(C_{10}C^{G+})_2$ /DNA complexes incubated as lane 5. Lane 7: as lane 6 in 3 mM final sodium dodecylsulfate before loading. Lane 8: 30  $\mu$ M pCMV-luc plasmid DNA.

e) Nanosizing DNA particles condensed with  $C_{10}C^{G+}$

Complexes were formed with plasmid CMV-Luc (5.6 kbp), with  $\lambda$  phage DNA (48 Kbp) and with T4 DNA (167 Kbp) in a concentration of 15  $\mu$ M bp in Tris-HCl (15 mM pH 8.4). After 24 h of incubation the measurements were carried out.

The results are shown in Fig. 6 (Fig. 6A: phage lambda. Fig. 6B: phage T4. Fig. 6C: CMV-Luc. 1 eq. = 30 $\mu$ M; 1.2 eq. = 36 $\mu$ M; 1.4 eq. = 42 $\mu$ M).

In case of monomolecular condensation of the DNA molecules the volume of the formed particles is directly proportional to the length of DNA:

volume=constant x length of DNA (bp).

In case of spheric particles the volume is proportional to the third power of the diameter ( $vol=4\pi R^3/3$ ), which can be presented by the following equation:

particle diameter = constant x (length of DNA (bp))<sup>1/3</sup>. When the minimum particle size derived from different DNAs (Fig. 7B) was plotted as a function of the cubic root of their size (Fig. 7A), one could draw a straight line through the points including the origin. This is the proof for monomolecular condensation.

f) Transfection of lipophilic alcohol cysteine amide (C<sub>10</sub>C<sup>G+</sup>)/DNA complexes into the cell line BNL CL.2

24 h before transfection the cells (obtained from ATCC) were distributed in a 24 well culture plate (50.000 cells per well. Cells were cultured in 75-cm<sup>2</sup> flask (Costar) in Dulbecco's modified Eagle's medium (DMEM, GIBCO), streptomycin at 100 $\mu$ g/ml (GIBCO), penicillin at 100 international units/ml (GIBCO); and glutamine (glutamax) at 0.286 g/ml (Lancaster) at 37°C in humidified 5% CO<sub>2</sub>-containing atmosphere.

Complexes with the plasmid CMV-Luc were formed by adding an aliquot of a concentrated C<sub>10</sub>C<sup>G+</sup> solution to a solution of the plasmid (30  $\mu$ M bp) in oxygen-saturated Tris-HCl 15 mM pH 8.4. The solution was then incubated in oxygen atmosphere for 24 h. Immediately before transfection, the medium was replaced by fresh medium without serum. 100  $\mu$ l of the transfection solution containing the complexes were added per well (2  $\mu$ g DNA). 3 h after the transfection 1 % serum

was added, 1 h later 9 % serum. 6 h after transfection the transfection medium was replaced by a medium complemented to 10 % serum. 24 h later luciferase expression was determined with a commercially available kit (Promega) in a luminometer (Berthold). Each experiment was conducted in duplicate, the results are given as light units per mg protein (bicinchoninic acid (BCA) test, Pierce). As an internal standard a DNA complex containing 10 charge equivalent of PEI (polyethylenimine, 25 kDa) was used (Fig. 8).


## Example 2

### a) Synthesis of a lipophilic alcohol cysteine ester detergent

The synthesis was carried out according to the scheme depicted in Fig. 9.

#### Step 1

#### Manufacture of N,S-Bis-tert-butoxycarbonyl-L-cysteine



945 mg L-cysteine chlorohydrate (6 mmol) were dissolved in 10 ml deionized water in which gases were removed by vacuum. 2.625 g BocOBoc (12 mmol) in 10 ml THF and 5.4 ml triethylamine (39 mmol) were added to this solution. After two days of stirring under argon atmosphere and ambient temperature, the reaction medium was evaporated to a volume slightly below 10 ml. Then 10 ml deionized water were added and the aqueous phase was washed with ether in order to remove the remaining non-reacted BocOBoc. Next the aqueous phase was acidified to pH 3 with saturated citric acid and extracted with ether (3 x 60 ml). The ether phases were washed with 0.5 M citric acid (2 x 100 ml), dried



over  $\text{MgSO}_4$  and evaporated. Chromatography over a silica column (elution with a  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  gradient containing 1 % acetic acid from 0 % to 2 %) yielded 1.34 g N,S-bis-tert-butoxycarbonyl-cysteine (4,2 mmol; yield=70 %).


TLC :  $R_f$  ( $\text{CH}_2\text{Cl}_2$ , MeOH 5%, AcOH 1%) = 0,5.

The structure of the obtained product was confirmed by nuclear magnetic resonance  $\text{NMR}^1\text{H}$  ( $\text{CDCl}_3$ ) and the chemical shifts  $\delta$  (ppm): 1,46 (s, 9H, N-Boc); 1,50 (s, 9H, S-boc); 3,22 (dd,  $J_1=15$  Hz,  $J_2=7$  Hz, 1H, Ha); 3,36 (dd,  $J_1=15$  Hz,  $J_2=5$  Hz, 1H, Ha); 4,34-4,57 (m, 1H, Hb); 5,45 (d,  $J=7,2$  Hz, 1H, Hc); 6,34 (brs, 1H, Hd).

MS (FAB+) : 322,1 ( $\text{MH}^+$ ).

## Step 2

Manufacture of a lipophilic alcohol ester of N,S-Bis-tert-butoxycarbonyl-L-cysteine



To a solution of lipophilic alcohol (1.2 mmol) in 2.5 ml anhydrous dichloromethane 321 mg N,S-bis-tert-butoxycarbonyl-cysteine (1 mmol) and 24 mg 4-dimethylaminopyridine (0.2 mmol) were added. The solution was then cooled to  $0^\circ\text{C}$  and 268 mg DCC (1.3 mmol; or EDC) were added. The solution was stirred for 2 h at  $0^\circ\text{C}$  and then over night at room temperature. Then the reaction medium was evaporated to dryness and the residue was resuspended in 10 ml ethylacetate. The suspension was filtered and the filtrate was diluted in


10 ml ethylacetate. The organic phase was washed with 20 ml distilled water, 20 ml aqueous 5 % sodium carbonate solution and 20 ml distilled water. The organic phase was dried over  $\text{MgSO}_4$  and then evaporated to dryness. The obtained oil was finally chromatographed over a silica column (elution with hexane/ethylacetate from 0 % to 7 %) in order to obtain a translucent oil. In the case of C10 cysteine ( $n=2$ ) a yield of 73 % was obtained. TLC (hexane, AcOEt 10 %)  $R_f=0.50$

The structure of the obtained product was confirmed by nuclear magnetic resonance  $\text{NMR}^1\text{H}$  ( $\text{CDCl}_3$ ) the chemical shifts  $\delta$  (ppm) were determined as follows: 0,90 (t,  $J=6,9$  Hz, 3H,  $\text{H}_5$ ); 1,25-1,42 (m, 12H,  $\text{H}_3$ ); 1,46 (s, 9H, N-Boc); 1,51 (s, 9H, S-Boc); 1,56-1,71 (m, 4H,  $\text{H}_2$ ,  $\text{H}_4$ ); 3,18-3,38 (m, 2H,  $\text{H}_a$ ); 4,14 (t,  $J=6,6$  Hz, 2H,  $\text{H}_1$ ); 4,50-4,58 (m, 1H,  $\text{H}_b$ ); 5,30-5,38 (m, 1H,  $\text{H}_b$ ); 5,30-5,38 (m, 1H,  $\text{H}_c$ ).

MS (FAB $^+$ ): 462,4 ( $\text{MH}^+$ ).

### Step 3

Manufacture of a lipophilic alcohol cysteine ester



0.2 mmol of the lipophilic alcohol ester of N,S-bis-tert-butoxycarbonyl-L-cysteine dissolved in 1.5 ml trifluoroacetic acid were stirred in argon atmosphere for 1 h. The reaction medium was evaporated and the obtained translucent oil was

dissolved in 1 ml deuterio-ethanol and kept under argon atmosphere at  $-80^{\circ}\text{C}$ . The measurement of thiol groups with Ellman's reagent (Riddles et al., 1979) showed that the deprotection reaction was quantitative.

In the case of C10 cysteine ( $n=2$ ):

The structure of the obtained product was confirmed by nuclear magnetic resonance  $\text{NMR}^1\text{H}$  ( $[\text{D}_6]$ ethanol) and the chemical shifts  $\delta$  (ppm) were determined as follows: 0,91 (t,  $J=6,8$  Hz, 3H,  $\text{H}_5$ ); 1,24-1,48 (m, 14H,  $\text{H}_3$ ,  $\text{H}_4$ ); 1,66-1,78 (m, 2H,  $\text{H}_2$ ); 3,06-3,22 (m, 2H,  $\text{H}_a$ ); 4,18-4,40 (m, 3H,  $\text{H}_b$ ,  $\text{H}_1$ ).

MS (FAB+) : 262,2 ( $\text{MH}^+$ ).

b) Determination of the critical micelle concentration (c.m.c.) of the lipophilic alcohol cysteine esters with and without DNA

i) c.m.c. of a detergent with C8, C10, C11 and C12 cysteine

Measurement of the c.m.c. was accomplished with a Langmuir balance in a MES buffer (20 mM pH 6) containing 10 mM DTT. When representing the surface tension as a logarithmic function of the detergent concentration a break at the c.m.c. was observed (Fig. 10).

Applying this method c.m.c.'s of the compounds having different chain length (C8, C10, C11, C12) were determined.

Cn-Cysteine	CMC
C8	> 2 mM
C10	320 $\mu$ M
C11	80 $\mu$ M
C12	15 $\mu$ M

ii) c.m.c. of C10 and C11 cysteine with and without DNA. In an analogous manner as above the c.m.c. value of C10 cysteine and C11 cysteine was determined, the buffer containing calf thymus DNA at a concentration of 30  $\mu$ M bp (Fig. 11A, B).

CnCysteine	CMC without DNA	CMC with DNA
C10	320 $\mu$ M	50 $\mu$ M
C11	80 $\mu$ M	32 $\mu$ M

c) Oxidation of C10 cysteine with and without DNA

The speed of the oxidation of C10 cysteine was determined by measuring the thiol groups, using Ellman's reagent (Riddles et al., 1979), as a function of time. The measurement was carried out in a solution of 60  $\mu$ M C10 cysteine in MES 20 mM pH 6 without DNA or in the presence of 30  $\mu$ M bp CMV-Luc (Fig. 12).


### Example 3

#### Synthesis of a lipophilic alcohol guanidyl-cysteine ester detergent

The synthesis was carried out according to the scheme depicted in Fig. 13.

#### Step 1

##### Manufacture of *S-tert*-butoxycarbonylcysteine-decylester



231 mg N,S-bis-*tert*-butoxycarbonyl-cysteine-decylester (0,5 mmol) were dissolved in 1.1 ml 2.2 N HCl/AcOEt. The solution was agitated for 1 h at ambient temperature and then evaporated to dryness. The obtained residue was taken up in 50 ml ethylacetate. The organic phase was washed twice with 25 ml 5 % (w/w) sodium hydrogencarbonate, dried over magnesium sulfate and then evaporated to dryness. The obtained oil was purified by silica chromatography (gradient 0 to 3 % methanol in dichloromethane) to obtain 141 mg of a yellow oil (0.39 mmol, yield=78 %).

$C_{18}H_{35}NO_4S$ ; 361,55 g/mol


$NMR^1H$  ( $CDCl_3$ );  $\delta$  ppm: 0,90 (t,  $J=7$  Hz, 3H,  $CH_3$ ); 1,20-1,42 (m, 14H,  $CH_3-O(CH_2)_7-CH_2CH_2O$ ); 1,50 (s, 9H,  $C(CH_3)_3$ ), 1,58-1,72 (m, 4H,  $CH_2-CH_2O$ ,

NH<sub>2</sub>); 3,03 (dd,  $J_1=14$  Hz,  $J_2=7$  Hz, 1H, CH-S); 3,26 (dd,  $J_1=14$  Hz,  $J_2=5$  Hz, 1H, CH-S); 3,71 (dd,  $J_1=7$  Hz,  $J_2=5$  Hz, 1H, CH-COO); 4,13 (t,  $J=6$  Hz, 2H, CH<sub>2</sub>-O).

MS (FAB+),  $m/z$  : 362,2 [MH<sup>+</sup>]; 306,2 [MH<sup>+</sup> - *t*-Butyl]; 262,2 [MH<sup>+</sup> - Boc].

## Step 2

Manufacture of N,N'-bis-*tert*-butoxycarbonyl-guanidinyl-S-*tert*-butoxycarbonylcysteine-decylester



To a solution of 99 mg of S-*tert*-butoxycarbonylcysteine-decylester (0.275 mmol) in 1 ml acetonitril 78 mg N,N'-bis-*tert*-butoxycarbonyl-pyrazole-1-carboxamidine (0.25 mmol) were added. The reaction medium was agitated for 2 days at ambient temperature, then evaporated to dryness. The obtained residue was purified by silica chromatography (gradient 0 to 7 % ethylacetate in hexane) to obtain 127 mg of a translucid oil (0.21 mmol, yield=84 %).


C<sub>29</sub>H<sub>53</sub>N<sub>3</sub>O<sub>8</sub>S; 603,82 g/mol

TLC : R<sub>f</sub> (10% AcOEt / Hexane) = 0,5.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  ppm: 0,9 (t, J=7 Hz, 3H, CH<sub>3</sub>); 1,25-1,42 (m, 14H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH<sub>2</sub>CH<sub>2</sub>O); 1,479 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,493 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,497 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,58-1,73 (m, 2H, CH<sub>2</sub>-CH<sub>2</sub>O); 3,31 (dd, J<sub>1</sub>=14 Hz, J<sub>2</sub>=5 Hz, 1H, CH-S); 3,50 (dd, J<sub>1</sub>=14 Hz, J<sub>2</sub>=5 Hz, 1H, CH-S); 4,05-4,20 (m, 2H, CH<sub>2</sub>-O); 5,15 (dt, J<sub>1</sub>=7 Hz, J<sub>2</sub>=5 Hz, 1H, CH-COO); 9,00 (d, J=5 Hz, 1H, NH-Boc); 11,42 (brs, 1H, NH-CN(NH)).

### Step 3

#### Manufacture of guanidyl-cysteine-decylester



30 mg of N,N'-bis-*tert*-butoxycarbonyl-guanidinyl-S-*tert*-butoxycarbonylcysteine-decylester (0.05 mmol) dissolved in 1 ml trifluoroacetic acid were agitated under argon atmosphere for 2 h at ambient temperature. The reaction medium was then evaporated to dryness and the obtained translucent oil was dissolved in 1 ml deuterio-ethanol. The solution was kept under argon atmosphere at -80°C. The yield of the reaction was determined by measuring the amount of thiol functions with Ellman's reagent (Riddles, et al., 1979). The reaction yield was 80 %.

C<sub>14</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>S; 303,46 g/mol

NMR<sup>1</sup>H (CD<sub>3</sub>CD<sub>2</sub>OD);  $\delta$  ppm: 0,90 (t, J=6 Hz, 3H, CH<sub>3</sub>); 1,25-1,47 (m, 14H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH<sub>2</sub>CH<sub>2</sub>O); 1,60-1,77 (m, 2H, CH<sub>2</sub>-CH<sub>2</sub>O); 2,98-3,27 (m, 2H, CH<sub>2</sub>-S); 4,12-4,30 (m, 2H, OCH<sub>2</sub>); 4,32-4,40 (m, 1H, CH-CONH).


## Example 4

### Synthesis of a lipophilic ornithyl-cysteine amide detergent

The synthesis was carried out according to the scheme depicted in Fig. 14.

#### Step 1

##### Manufacture of *S*-*tert*-butoxycarbonylcysteine hydrochloride



642 mg of N,S-bis-*tert*-butoxycarbonylcysteine (2 mmol) were dissolved in 3 ml 2.9 N HCl/AcOEt and the solution was agitated at ambient temperature for 20 min. 3 ml ether were added to the reaction medium and the obtained crystals were collected by filtration, washed with ether and finally dried under vacuum. Thereby 405 mg of white crystals were obtained (1.57 mmol, yield=79 %).


$C_8H_{16}NO_4ClS$ ; 257,74 g/mol

NMR<sup>1</sup>H (DCI 0,1 M);  $\delta$  ppm: 1,44 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 3,31 (dd,  $J_1=15$  Hz,  $J_2=7$  Hz, 1H, CH-S); 3,49 (dd,  $J_1=15$  Hz,  $J_2=5$  Hz, 1H, CH-S); 4,33 (dd,  $J_1=7$  Hz,  $J_2=5$  Hz, 1H, CH-CO<sub>2</sub>).

MS (FAB+),  $m/z$  : 222,0 [MH<sup>+</sup>]; 166,0 [MH<sup>+</sup> - *tert*-Butyl].



## Step 2

Manufacture of N,N'-bis-*tert*-butoxycarbonylornithyl-S-*tert*-butoxycarbonylcysteine


To a solution of N,N'-bis-*tert*-butoxycarbonylornithine (160 mg; 0.48 mmol) in 1 ml dichloromethane 60 mg of N-hydroxy-succinimide (0.52 mmol) were added. The reaction mixture was cooled to 0°C and 99 mg N,N'-dicyclohexylcarbodiimide (0.48 mmol) were added. After 2 h of agitating at 0°C, 130 mg hydrochloride S-*tert*-butoxycarbonylcysteine (0.50 mmol), which had been dissolved in 1 ml methanol containing 234 µl triethylamine (1.68 mmol), were added, then the solution was agitated over night at ambient temperature. The reaction medium was then evaporated to dryness, taken up in 10 ml ethylacetate and then filtered. After dilution with 50 ml ethylacetate, the filtrate was washed twice with 25 ml 5 % (w/w) citric acid, dried over magnesium sulfate and then evaporated to dryness. The obtained residue was purified by silica chromatography (gradient 2 to 15 % methanol in dichloromethane) to obtain 242 mg of a white solid (0.45 mmol, yield=94 %).

$C_{23}H_{41}N_3O_9S$ ; 535,66 g/mol

NMR<sup>1</sup>H (CD<sub>3</sub>OD);  $\delta$  ppm: 1,42 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,45 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,46 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,47-1,88 (m, 4H, CH<sub>2</sub>CH<sub>2</sub>-CH<sub>2</sub>NHBoc); 3,04 (t, J=6 Hz, 2H, CH<sub>2</sub>-NHBoc); 3,13 (dd, J<sub>1</sub>=14 Hz, J<sub>2</sub>=7 Hz, 1H, CH-S); 3,45 (dd, J<sub>1</sub>=14 Hz, J<sub>2</sub>=4 Hz, 1H, CH-S); 4,0-4,1 (m, 1H, CH<sub>2</sub>CH<sub>2</sub>-CH-CONH); 4,40 (dd, J<sub>1</sub>=7 Hz, J<sub>2</sub>=4 Hz, 1H, CH-CO<sub>2</sub>).

### Step 3

Manufacture of N,N'-bis-*tert*-butoxycarbonylornithyl-S-*tert*-butoxycarbonylcysteine-n-alkylamide



To a solution of N,N'-bis-*tert*-butoxycarbonylornithyl-S-*tert*-butoxycarbonylcysteine (100 mg; 0.187 mmol) in 0.5 ml dichloromethane 26 mg N-hydroxysuccinimide (0.224 mmol) were added. The reaction mixture was cooled to 0°C and 42 mg N,N'-dicyclohexylcarbodiimide (0.205 mmol) were added. After 2 h of reaction at 0°C, n-alkylamine (0.205 mmol) was introduced and the solution was agitated over night at ambient temperature. Then the reaction medium was evaporated to dryness, taken up in 5 ml ethylacetate and then filtered. After dilution in 25 ml ethylacetate, the filtrate was washed in subsequent steps with 10 ml water, 10 ml 5 % (w/w) sodium hydrogencarbonate and 10 ml water; dried over magnesium sulfate and evaporated to dryness. The

obtained residue was purified by silica chromatography (gradient 0 to 1 % methanol in dichloromethane) to obtain a white solid.

In the case of N,N'-bis-*tert*-butoxycarbonylornithyl-S-*tert*-butoxycarbonylcysteine-dodecylamide 85 mg of a white solid (0.121 mmol; yield=65 %) were obtained.


$C_{35}H_{66}N_4O_8S$ ; 703,00 g/mol

TLC : R<sub>f</sub> (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) = 0,5.

NMR<sup>1</sup>H (CD<sub>3</sub>OD);  $\delta$  ppm: 0,89 (t, J=7 Hz, 3H, CH<sub>3</sub>); 1,25-1,35 (m, 18H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>9</sub>-CH<sub>2</sub> CH<sub>2</sub>NH); 1,42 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,45 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,49 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); 1,5-1,9 (m, 6H, CH<sub>2</sub>CH<sub>2</sub>-CH<sub>2</sub>NHBoc, CH<sub>2</sub>-CH<sub>2</sub>NHCOCH); 3,00 (t, J=6 Hz, 2H, CH<sub>2</sub>- NHBoc); 3,04-3,50 (m, 4H, CH<sub>2</sub>-S, CH<sub>2</sub>-NHCOCH); 3,94 (dd, J<sub>1</sub>=8 Hz, J<sub>2</sub>=5 Hz, 1H, CH<sub>2</sub>CH<sub>2</sub>-CH-CONH); 4,48 (dd, J<sub>1</sub>=8 Hz, J<sub>2</sub>=5 Hz, 1H, CH-CONHCH<sub>2</sub>).

#### Step 4

Manufacture of ornithyl-cysteine-n-alkylamide



0.11 mmol N,N'-bis-*tert*-butoxycarbonylornithyl-S-*tert*-butoxycarbonylcysteine-n-alkylamide dissolved in 1 ml trifluoroacetic acid were agitated under argon

atmosphere at ambient temperature for 1.5 h. The reaction medium was evaporated and the obtained translucent oil was diluted in 1 ml deuterio-ethanol. The solution was kept under argon atmosphere at  $-80^{\circ}\text{C}$ . The yield of the reaction was determined by measuring the amount of thiol functions with Ellman's reagent (Riddles, et al., 1979). In the case of ornithyl-cysteine-dodecylamide, the yield was 84 %.

$\text{C}_{20}\text{H}_{42}\text{N}_4\text{O}_2\text{S}$ ; 402,64 g/mol

$\text{NMR}^1\text{H}$  ( $\text{CD}_3\text{OD}$ );  $\delta$  ppm: 0,89 (t,  $J=7$  Hz, 3H,  $\text{CH}_3$ ); 1,25-1,38 (m, 18H,  $\text{CH}_3$ - $(\text{CH}_2)_9$ - $\text{CH}_2$   $\text{CH}_2\text{NH}$ ); 1,45-1,96 (m, 6H,  $\text{CH}_2\text{CH}_2$ - $\text{CH}_2\text{NHBoc}$ ,  $\text{CH}_2$ - $\text{CH}_2\text{NHCOCH}$ ); 2,80-3,50 (m, 6H,  $\text{CH}_2$ -  $\text{NH}_3^+$ ,  $\text{CH}_2$ -S,  $\text{CH}_2$ - $\text{NHCO}$ ); 3,95-4,0 (m, 1H,  $\text{CH}_2\text{CH}_2$ - $\text{CH-CONH}$ ); 4,42-4,48 (m, 1H,  $\text{CH-CONHCH}_2$ ).


### Example 5

#### Synthesis of a lipophilic alcohol galactosyl-cysteine ester detergent

The synthesis was carried out according to the scheme depicted in Fig. 15.

#### Step 1

##### *S-tert*-butoxycarbonylcysteine-bromoacetamide-decylester



To a solution containing 108 mg of *S*-*tert*-butoxycarbonylcysteine-decylester (0.30 mmol) in 1 ml dichloromethane, 63  $\mu$ l triethylamine (0.45 mmol) and then 86 mg bromoacetic acid anhydride (0.33 mmol) were added. The reaction medium was agitated for 1 h at ambient temperature and then evaporated to dryness. The obtained residue was purified by silica chromatography (gradient 5 to 10 % ethylacetate in hexane) to obtain 88 mg of a translucent oil (0.18 mmol, yield=61 %).

$C_{20}H_{36}BrNO_5S$ ; 482,48 g/mol


TLC:  $R_f$  (20% AcOEt / Hexane) = 0,5.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  (ppm) : 0,90 (t,  $J=7$  Hz, 3H, CH<sub>3</sub>); 1,25-1,40 (m, 14H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH<sub>2</sub>CH<sub>2</sub>O); 1,50 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 1,60-1,75 (m, 2H, CH<sub>2</sub>-CH<sub>2</sub>O); 3,26 (dd,  $J_1=15$  Hz,  $J_2=6$  Hz, 1H, CH-S); 3,42 (dd,  $J_1=15$  Hz,  $J_2=4$  Hz, 1H, CH-S); 3,90 (s, 2H, CH<sub>2</sub>-Br); 4,17 (t,  $J=7$  Hz, CH<sub>2</sub>-O); 4,79 (ddd,  $J_1=7$  Hz,  $J_2=6$  Hz,  $J_3=4$  Hz, 1H, CH-COO); 7,20-7,35 (m, 1H, NH).

MS (FAB+),  $m/z$  : 482,1 and 484,1 [ $MH^+$ ]; 426,1 and 428,1 [ $MH^+ - t\text{-Butyl}$ ]; 382,1 and 384,1 [ $MH^+ - Boc$ ].

## Step 2

Manufacture of *S*-*tert*-butoxycarbonylcysteine-thiogalactosylacetamide-decylester



To a solution containing 48 mg *S-tert*-butoxycarbonylcysteine-bromoacetamide-decylester (0.1 mmol) in 1 ml dimethylformamide, 23 mg 1-thio-D-galactopyranose (0.1 mmol) were added. The solution was agitated for 3 h at ambient temperature and then evaporated to dryness. The obtained residue was purified by silica chromatography (gradient 3 to 20 % methanol in dichlormethane) to obtain 52 mg of a glassy solid (0.087 mmol, yield=87 %).

$C_{26}H_{47}NO_{10}S_2$ ; 597,79 g/mol


TLC :  $R_f$  (10% MeOH /  $CH_2Cl_2$ ) = 0,4

$NMR^1H$  ( $CD_3OD$ );  $\delta$  ppm : 0,90 (t,  $J=7$  Hz, 3H,  $CH_3$ ); 1,25-1,43 (m, 14H,  $CH_3-(CH_2)_7-CH_2CH_2O$ ); 1,48 (s, 9H,  $C(CH_3)_3$ ), 1,58-1,73 (m, 2H,  $CH_2-CH_2O$ ); 3,12 (dd,  $J_1=14$  Hz,  $J_2=8$  Hz, 1H, CH-S); 3,34 (s, 2H, CO- $CH_2$ -S); 3,25-3,88 (m, 7H, CH-S,  $H_2$ ,  $H_3$ ,  $H_4$ ,  $H_5$ ,  $H_6$ ); 4,08-4,17 (m, 2H,  $CH_2-O$ ); 4,41 (d,  $J=9$  Hz,  $H_1$ ); 4,55-4,70 (m, 1H, CH-COO).

MS (FAB+),  $m/z$  : 620,2 [ $MNa^+$ ]; 598,2 [ $MH^+$ ]; 564,2 [ $MNa^+ - t\text{-Butyl}$ ]; 542,2 [ $MH^+ - t\text{-Butyl}$ ]; 520,2 [ $MNa^+ - Boc$ ].

### Step 3

Manufacture of cysteine-thiogalactosylacetamide-decylester




The quantitative yield of the reaction was determined by measuring the amount of thiol functions with Ellman's reagent (Riddles, et al., 1979).


NMR<sup>1</sup>H (CD<sub>3</sub>CD<sub>2</sub>OD); δ ppm : 0,90 (t, J=7 Hz, 3H, CH<sub>3</sub>); 1,20-1,43 (m, 14H, CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH<sub>2</sub>CH<sub>2</sub>O); 1,60-1,76 (m, 2H, CH<sub>2</sub>-CH<sub>2</sub>O); 2,85-3,08 (m, 2H, CH<sub>2</sub>-S); 3,35-4,00 (m, 8H, H<sub>2</sub>, H<sub>3</sub>, H<sub>4</sub>, H<sub>5</sub>, H<sub>6</sub>, CO-CH<sub>2</sub>-S); 4,07-4,28 (m, 2H, CH<sub>2</sub>-O); 4,43 (d, J=9 Hz, 1H); 4,58-4,70 (m, 1H, CH-COO).

### Example 6

In order to form monodisperse DNA transfection particles which are stabilised by non-lipid molecules, an alternative vector type, based on spermine-N1, N12-bis-cysteineamide (SC<sub>2</sub>) was synthesized.



## a) Synthesis of spermine-N1, N12-bis-cysteineamide



N,N'-bis-tert-butoxycarbonyl-N,N'-(2-cyanoethyl)-1,4-diaminobutane 2.

A solution containing 2 ml 1,4-diaminobutane 1 (20 mmol), 2.63 ml acrylonitrile (40 mmol) in 10 ml acetonitrile was stirred at ambient temperature under argon atmosphere and exposed to under darkness. After 18 h of stirring, 10.835 g BocON (44 mmol) and 6.2 ml triethylamine (44 mmol), were introduced into the solution. After three days the reaction medium was diluted in 100 ml ether. The organic phase was washed with 2 M NaOH 2 x 50 ml), 50 ml distilled water and



50 ml 5 % (w/w) citric acid. The organic phase was then dried over  $\text{MgSO}_4$  and then evaporated to yield 4.27 g of a white solid. The latter was crystallized in ether which yielded 3.50 g of compound 2 (8.9 mmol, yield=44 %) in the form of white crystals.

$\text{C}_{20}\text{H}_{34}\text{N}_4\text{O}_4$ ; 394,52 g/mol.

TLC :  $R_f$  ( $\text{CH}_2\text{Cl}_2$  96%/MeOH 4%) = 0,4.

NMR  $^1\text{H}$  ( $\text{CDCl}_3$ );  $\delta$  ppm : 1,29-1,65 (m, 22H,  $(\text{CH}_2)_2\text{-CH}_2\text{-CH}_2$ ,  $\text{C}(\text{CH}_3)_3$ ); 2,50-2,68 (m, 4H,  $\text{CH}_2\text{-N}(\text{Boc})\text{-(CH}_2)_2\text{-CN}$ ); 3,19-3,32 (m, 4H,  $\text{N}(\text{Boc})\text{-CH}_2\text{-CH}_2\text{-CN}$ ); 3,44 (t,  $J=6,7$  Hz, 4H,  $\text{CH}_2\text{-CN}$ ). (The hydrogen atoms assigned to the signal are in bold print.)

N,N'-bis-tert-butoxycarbonyl-N,N'-(2-aminopropyl)-1,4-diaminobutane 3.

A solution containing 1.176 g N',N-Di-tert-butoxycarbonyl-N,N'-(2-cyanoethyl)-1,4-diaminobutane 2 (3 mmol) in 6 ml methanol and 2 ml 2 M NaOH (4 mmol) was stirred in the presence of a catalytic amount of Raney nickel under hydrogen atmosphere. After 4 h of stirring the nickel was removed by celite filtration. The filtrate was evaporated and the obtained residue resuspended in 50 ml dichloromethane. The organic phase was then washed with 50 ml 2 M NaOH, dried over  $\text{MgSO}_4$  and then evaporated to obtain 810 mg of compound 3 (2 mmol; yield=67 %) in form of a yellow viscous liquid.

$\text{C}_{20}\text{H}_{42}\text{N}_4\text{O}_4$ ; 402,58 g/mol.

TLC:  $R_f$  ( $\text{CH}_2\text{Cl}_2$  20%/MeOH 60%/  $\text{NEt}_3$  20%) = 0,4.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  ppm : 1,35-1,55 (m, 8H, (CH<sub>2</sub>)<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>, NH<sub>2</sub>); 1,45 (s, 18H, 2xC(CH<sub>3</sub>)<sub>3</sub>); 1,64 (quint., J=6,8 Hz, 4H, CH<sub>2</sub>-CH<sub>2</sub>-NH<sub>2</sub>); 2,69 (t, J=6,7 Hz, 4H, CH<sub>2</sub>-NH<sub>2</sub>); 3,10-3,32 (m, 8H, CH<sub>2</sub>-N(Boc)-CH<sub>2</sub>).

Spermine-N4,N9-bis-tert-butoxycarbonyl-N1,N12-bis-cysteine  
(N,S-bis-tert-butoxycarbonyl)amide 6.

To a solution containing 242 mg N,N'-bis-tert-butoxycarbonyl-N,N'-(2-aminopropyl)-1,4-diaminobutane 3 (0.6 mmol) and 388 mg N,S-Bis-tert-butoxycarbonyl-cysteine (1.2 mmol) in 1.5 ml dichloromethane, 248 mg DCC (1.2 mmol) dissolved in 1.5 ml dichloromethane were added. The solution was stirred for one day filtered in order to remove the formed DCU and then evaporated. The residue was resuspended in 100 ml ethylacetate, washed with distilled water (100 ml), an aqueous sodium carbonate solution 0.5 M (100 ml), an aqueous saturated NaCl solution (100 ml), an aqueous citric acid solution 0.2 M (100 ml) and finally with an aqueous saturated NaCl solution (100 ml). The organic phase was dried over MgSO<sub>4</sub> and then evaporated. The product was then run over a silica column in order to obtain 401 mg of compound 6 (0.4 mmol; yield=66 %) in the form of a white solid.

C<sub>46</sub>H<sub>84</sub>N<sub>6</sub>O<sub>14</sub>S<sub>2</sub>; 1009,35 g/mol.

TLC : R<sub>f</sub> (CH<sub>2</sub>Cl<sub>2</sub> 97%/MeOH 3%) = 0,5.

NMR<sup>1</sup>H (CDCl<sub>3</sub>);  $\delta$  ppm : 1,50-1,89 (m, 8H, 2x(CH<sub>2</sub>)<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>, 2xCH<sub>2</sub>-CH<sub>2</sub>-NH-CO); 1,44 (s, 18H, 2xC(CH<sub>3</sub>)<sub>3</sub>); 1,45 (s, 18H, 2xC(CH<sub>3</sub>)<sub>3</sub>); 1,50 (s, 18H, 2xC(CH<sub>3</sub>)<sub>3</sub>); 3,04-3,32 (m, 16H, (CH<sub>2</sub>)<sub>3</sub>-CH<sub>2</sub>-NBoc, CH<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>-NH-CO, CH<sub>2</sub>-NH-CO, CH<sub>2</sub>-S-CO); 4,23-4,40 (m, 2H, CH-CH<sub>2</sub>-S-Boc); 5,37-5,54 (m, 2H, NH-Boc); 7,32-7,46 (m, 2H, CH<sub>2</sub>-NH-CO).

MS (FAB<sup>+</sup>) : 1009,3 (MH<sup>+</sup>); 909,2 (MH<sup>+</sup>-Boc); 809,3 (MH<sup>+</sup>-2Boc); 709,2 (MH<sup>+</sup>-3Boc); 609,2 (MH<sup>+</sup>-4Boc); 509,2 (MH<sup>+</sup>-5Boc); 409,1 (MH<sup>+</sup>- 6Boc).

Spermine-N1,N12-bis-cysteineamide 7.

50 mg of compound 6 (0.05 mmol) dissolved in 1 ml trifluoroacetic acid and 1 ml dichloromethane were stirred under argon atmosphere for 2 h. The reaction medium was then evaporated and 85 mg of a yellowish viscous liquid is obtained. The product was kept in the presence of ca. 11 equivalents of trifluoroacetic acid in order to avoid oxydation of the functional thiol groups. The measurement of thiol groups with Ellman's reagent (Riddles et al., 1979) showed that the deprotection reaction was quantitative.

C<sub>16</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub>S<sub>2</sub>; 408,64 g/mol.

NMR<sup>1</sup> H (D<sub>2</sub>O);  $\delta$  (ppm): 1,64-1,96 (m, 8H, (CH<sub>2</sub>)<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>-NH-CO); 2,90-3,09 (m, 12H, CH<sub>2</sub>)<sub>3</sub>-CH<sub>2</sub>-NBoc, CH<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>-NH-CO, CH<sub>2</sub>-NH-CO); 3,21-3,37 (m, 4H, CH<sub>2</sub>-SH); 4,04-4,15 (m, 2H, CH-CH<sub>2</sub>-SH).

MS (FAB<sup>+</sup>) : 410,1 (MH<sup>+</sup>).

## b) Biophysical characterisation of spermine-N1,N12-bis-cysteineamide

### i) UV spectroscopy

The characterisation of the formed particles by UV spectroscopy was performed for different reasons. DNA in solution has a characteristic absorption spectrum between 240 and 310 nm. The absorption (optical density) has a maximum at 260 nm and 0 towards 310 nm. A change in DNA conformation should change

the profile of the absorption spectrum. Moreover, the formation of particles results in an enhancement of the diffusion which can be perceived in UV by an enhancement of optical density. When the wave length is adjusted to a value slightly above 310 nm (which is the wave length at which the DNA in solution does not absorb) one can monitor the effect of particle formation.

Calf thymus DNA was complexed with spermine under conditions optimal for obtaining toroid structures as described by Naroditsky et al. (76  $\mu$ M DNA bases, 65 mM spermine, 25 mM NaCl). The absorption observed between 230 and 330 nm increased during 10 min while complexation of DNA took place. Consequently, a reduction of the optical density could be detected in the range of 260 nm, which is the absorption maximum of DNA), while it remained stable towards 300 nm. Finally the absorption stabilised after one and a half hours (Fig.16A).

When the NaCl concentration was raised to 100 mM, the observed spectrum was identical with the spectrum of the DNA that had been observed before complexation with spermine (Fig. 16B).

It could be concluded from the above experiment that the condensation with spermine is visible in UV. Moreover it could be shown that a reversion of the process takes place when the ionic strength of the medium is raised.

The same experience as with the above experiments was made in the presence of spermine-N1,N12-bis-cysteineamide (SC<sub>2</sub>) instead of spermine at the identical concentration (Fig. 16C).

The complexation kinetics of DNA by SC<sub>2</sub> is comparable to that obtained with spermine. The determination of thiol functions with Ellman's reagent (Riddles et al., 1979) showed that after 10 min 50 % of the thiol groups were oxydised, when no oxygen was present except for the oxygen in the water (the solubility of oxygen in an 1 M NaCl aqueous solution is 0.8 mM). Furthermore, augmentation

of the NaCl concentration one and a half hours after mixing SC<sub>2</sub> and DNA had only a minor effect on the absorption spectrum as compared with spermine. At 100 mM NaCl, the absorption at 330 nm was 81 % as compared to the maximum optical density observed at 25 mM NaCl; at 150 mM NaCl was still 71 %.

Consequently, SC<sub>2</sub> complexes and compacts DNA in the same manner as spermine. On the other hand, the formed particles seemed to be more stable vis à vis the ionic strength of the medium, which is in relation with the oxydation of the thiol functions.

## ii) Agarose gel electrophoresis

The stability of the particles formed either with spermine or with SC<sub>2</sub> (76 µM bases RSV-Luc, 65 µM spermine or SC<sub>2</sub>, 25 mM NaCl, pH 6.5; 2 hrs oxydation) was tested by agarose gel electrophoresis (1 %; Tris buffer pH 6.5). It could be observed that the compacted DNA, which is more bulky and less charged, was migrating less or not at all in the agarose gel. (Fig. 17)

The particles formed with spermine were not stable under the conditions that were used for electrophoresis (identical migration of DNA alone and of DNA complexed with spermine; lanes 1 and 2). The particles formed with SC<sub>2</sub> were stable (lane 3). The DNA-SC<sub>2</sub> particles remained relatively stable even at elevated ionic strength (lane 5). The stability of the complexes is due to the oxydation of SC<sub>2</sub>. Consequently, if one adds a reducing agent of the disulfide bridges to a solution of DNA complexed with SC<sub>2</sub>, the complexes are no longer stable under the conditions used for electrophoresis.

### Example 7

Size measurement of particles resulting from the interaction of a  $(C_{10}C^{G+})_2$ /DNA complex with different amounts of PEI 25KDa

The solution was prepared by adding detergent  $C_{10}C^{G+}$  (30  $\mu$ M) to a pCMVL DNA solution (30  $\mu$ M phosphate) in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic conditions during 24 h. Then, a desired amount of PEI 25 KDa (Aldrich) was added and the size measurement was done five minutes later by Dynamic Light Scattering as described by Blessing et al. (1998) Proc.Natl. Acad. Sci. USA, 95 (4), 1427-1431 (Fig. 18).

### Example 8

Size measurement of  $(C_{10}C^{G+})_2$ /PEI 25KDa-Gal4/DNA complexes

The complex solution was prepared by adding detergent  $C_{10}C^{G+}$  (30  $\mu$ M) to a pCMVL DNA solution (30  $\mu$ M phosphate) in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic conditions during 24 h. Then, 10 eq. of PEI 25KDa-Gal4 was added. (PEI-Gal4 was obtained by reductive amination between PEI25K and tetragalactose ( $Gal\alpha 3GalB4Gal\alpha 3Gal$ ) as described by Zanta et al., 1997.) Measurements were carried 1 min after polymer addition (circles). 17 h later, a concentrated NaCl solution was added to a final concentration of 150 mM (triangles). As a control, pCMVL DNA was complexed with 10 eq. PEI 25KDa-Gal4 (squares) as described in Boussif et al., 1995 (Fig. 19). It was found that  $(C_{10}C^{G+})_2$ /PEI 25KDa-Gal4/DNA complexes are much smaller than PEI 25KDa-Gal4/DNA complexes.

### Example 9

#### Transfection of SKOV3 cells with $C_{10}C^{G+}$ /DNA/PEI 25KDa complexes

The solution was prepared by mixing pCMVL (30  $\mu$ M phosphate) with 30  $\mu$ M  $C_{10}C^{G+}$  in Tris/HCl 15 mM pH 8.4 buffer, and leaving the solution in aerobic conditions during 24 h. Then, the desired amounts of PEI 25KDa were added. The SKOV3 cells (ovarian carcinoma, European Collection of Animal Cell Cultures (E.C.A.C.C.)) were seeded at 50.000 cells per well in 24 well dishes 18 h before transfection. An aliquot of the complex mixture (corresponding to 2  $\mu$ g plasmid per well) was added to the cell maintained in serum-free RPMI 1640 medium. After 2 h 10 % of serum was added. Luciferase gene expression was monitored 24 h later. The DNA bar correspond to pCMVL alone (2  $\mu$ g plasmid per well). (Fig. 20)

### Example 10

#### Transfection of BNL CL.2 cells with $C_{10}C^{G+}$ /DNA/PEI 25KDa and $C_{10}C^{G+}$ /DNA/PEI 25KDa-Gal4 complexes

The solution was prepared by mixing pCMVL (30  $\mu$ M phosphate) with 30  $\mu$ M  $C_{10}C^{G+}$  in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic condition during 24 h. Then, a desired amount of PEI 25KDa or PEI 25KDa-Gal4 (5 % grafting per total amine) was added. Cells were seeded at 50.000 cells per well in 24-well dishes 18 h before transfection. An aliquot of the complex mixture (corresponding to 2  $\mu$ g plasmid per well) was added to the cells maintained in serum-free DMEM medium. After 2 h 10 % of serum was added. Luciferase gene expression was monitored 24 h later (Fig. 21).

### Example 11

Coating of  $(C_{10}C^{G+})_2$ /DNA complexes with a polycation linked to a protein

Size measurement of particles resulting from the interaction of  $(C_{10}C^{G+})_2$ /DNA complexes with a transferrin-polylysine conjugate (TfpL36; see Example 13). The complex solution was prepared by adding detergent  $C_{10}C^{G+}$  (30  $\mu$ M) to a pCMVL DNA solution (30  $\mu$ M phosphate) in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic conditions during 24 h. Then, a desired amount of PLL<sub>36</sub>-Tf (2 % grafting per total amine) was added. Measurement was done 1 min (open circles) and 30 min (filled circles) after polymer addition. Then, a concentrated NaCl solution was added to a final concentration of 15 mM (open triangles). 30 min later the particle size was redetermined (filled triangle) (Fig. 22). The results show that  $(C_{10}C^{G+})_2$ /DNA complexes can be coated with a polycation linked to a protein and remain small.

### Example 12

Measurement of the zeta potential of transferrin-polylysine-coated  $(C_{10}C^{G+})_2$ /DNA particles

The complex solution was prepared by adding detergent  $C_{10}C^{G+}$  (30  $\mu$ M) to a pCMVL DNA solution (30  $\mu$ M phosphate) in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic conditions during 24 h. Then, a desired amount of TfpL (2 % grafting per total amine) was added. Before the measurements, a concentrated NaCl solution was added to a final concentration of 150 mM (Fig. 23). The results show that transferrin-polylysine-coated  $(C_{10}C^{G+})_2$ /DNA particles remain negatively charged.



### Example 13

Transfection of K562 cells: effect of transferrin-polylysine on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes

For transfection, DNA/ $C_{10}C^{G+}$  complexes were prepared by first mixing 10 µg pCMVL in 1 ml of HEPES (15 mM, pH = 8.5) to a final concentration of 30 µM with  $C_{10}C^{G+}$  detergent to a final concentration of 30 µM (1 equivalent). The solutions were gently mixed and left to oxidize for 24 h at room temperature. Next the complexes were mixed with hTf-pL36 conjugate [a conjugate of human transferrin and poly-L-lysine, average molecular degree of polymerization of 36 lysine monomers; molar ratio of transferrin : polylysine = 1/1.5] in 50 µl of HEPES (15 mM, pH = 8.5) at a molar ratio of polylysine nitrogen atoms to DNA phosphate (N/P) of 0.1; 0.2; 0.4; 1.0 and incubated 30 min at room temperature.

K562 suspension cells (ATCC CCL 243) were grown in RPMI1640 supplemented with 10 % fetal calf serum (FCS), 1% L-glutamine and antibiotics, and incubated at 37°C. For transfection, cells were plated in a 24-well plate at a density of 500 000 cells per well. The culture medium was replaced by a mixture of 1.05 ml transfection complex and 1 ml of RPMI1640 (10% FCS, 1% L-glutamine, antibiotics) plus chloroquine to a final concentration of 100 µM. After 4 h at 37°C of incubation the transfection medium was replaced by 2 ml of fresh culture medium. Cells were harvested 24 h after transfection, washed in PBS and resuspended in 100 µl of Tris (0.25 M, pH=7.9). Cells were lysed by freeze-thaw cycles. The cell lysate was centrifuged for 10 min at 10 000g to pellet debris. Luciferase light units were recorded from 10 µl of the supernatant.

The light units shown in the Fig. 24 represent the total luciferase activity per sample of the transfected cells.

#### Example 14

Transfection of B16F10 cells: effect of transferrin-polylysine on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes

For transfection, DNA/ $C_{10}C^{G+}$  complexes were prepared by first mixing 5  $\mu$ g pCMV-Luc in 0.5 ml of HEPES (15 mM, pH = 8.5) to a final concentration of 30  $\mu$ M with  $C_{10}C^{G+}$  detergent to a final concentration of 30  $\mu$ M (1 eq) The solutions were gently mixed and left to oxidize for 24 h at room temperature. Next the complexes were mixed with hTf-pL36 conjugate in 50  $\mu$ l of HEPES (15 mM, pH = 8.5) at a molar ratio of polylysine nitrogen atoms to DNA phosphate (N/P) of 0.1; 0.2; 0.5; 1.0 and incubated 30 min at room temperature.

B16F10 adherent cells (NIH DCT Tumor Depository) were grown in DMEM supplemented with 10% fetal calf serum (FCS), 1% L-glutamine and antibiotics, and incubated at 37°C. Cells were transfected in 25 cm<sup>2</sup> tissue flasks. 400 000 cells per flask were plated 18 h before transfection. The culture medium was replaced by a mixture of 0.55 ml transfection complex and 1 ml of DMEM (10% FCS, 1% L-glutamine, antibiotics) plus chloroquine to a final concentration of 100  $\mu$ M.

After 4 h at 37°C of incubation the transfection medium was replaced by 2 ml of fresh culture medium.

Luciferase activity was assayed 24 h after transfection.

The results of the experiment are shown in Fig. 25.

### Example 15

Transfection of B16F10 cells: effect of inactivated adenovirus particles on the delivery of  $(C_{10}C^{G+})_2$ /DNA complexes

For transfection, DNA/ $C_{10}C^{G+}$  complexes were prepared by first mixing 5  $\mu$ g pCMV-Luc in 0.5 ml of HEPES (15 mM, pH = 8.5) with  $C_{10}C^{G+}$  detergent to a final concentration of 30  $\mu$ M (1 Eq.) The solutions were gently mixed and left to oxydize for 24 h at room temperature. In the next step to the complexes were added:

- 1) Biotinylated, 8-MOP(Methoxypsoralen)-inactivated adenovirus particles dl1014 ( $8.6 \times 10^9$  particles) treated with streptavidinylated polylysine(250) in 50  $\mu$ l of HEPES (15 mM, pH = 8.5) and incubated 30 min at room temperature.
- 2) Biotinylated 8-MOP-inactivated adenovirus particles dl1014 ( $8.6 \times 10^9$  particles) mixed with polyethylenimine (PEI, molecular weight 25 kDa) in 50  $\mu$ l of HEPES (15 mM, pH = 8.5) at a molar ratio of PEI nitrogen atoms to DNA phosphate (N/P) of 0.4 or 1.0 and incubated 30 min at room temperature.

After a further 30 min, the complexes were used for the transfection experiment.

B16F10 adherent cells were grown in DMEM supplemented with 10% fetal calf serum (FCS), 1% L-glutamine and antibiotics, and incubated at 37°C. Cells were transfected in 25 cm<sup>2</sup> tissue flasks. 500 000 cells per flask were plated 18 h before transfection. The culture medium was replaced by a mixture of 0.55 ml transfection complex and 1 ml of DMEM (10% FCS, 1% L-glutamine, antibiotics).

After 4 h at 37°C of incubation, to the transfection medium 1 ml of fresh culture medium was added.

The cells were harvested 24 h after transfection and extracts were prepared. The resulting luciferase activity (corresponding to 500 000 cells) is shown in Fig. 26.

### Example 16

#### Complex formation and concentration for *in vivo* application

Complexes were formed with pCMVL plasmid DNA and detergent  $C_{10}C^{G+}$  by addition of a concentrated  $C_{10}C^{G+}$  stock solution (7.2 mM in ethanol; after determined by the thiol assay with Elmann's reagent) to a solution of pCMVL plasmid DNA in HEPES buffer (15 mM, pH = 8.5).

80  $\mu$ g pCMV-Luc DNA was added to a final concentration of 30  $\mu$ M (in 8 ml of buffer) before addition of the detergent.  $C_{10}C^{G+}$  was injected to a final concentration of:

- 1) 30  $\mu$ M (1 eq)
- 2) 21  $\mu$ M (0.7 eq)

The solutions were gently mixed and left to oxidize for 24 h at room temperature. In the next step, 0.8 ml of 50% glucose was added to bring the solutions to 5% glucose concentration.

The samples were concentrated with Vivaspin 4 concentrators, 100 000 MW membrane. After centrifugation at up to 4000 rpm, 0.3 ml of complexes containing

- 1) 44  $\mu$ g pCMVL DNA (55% yield)
- 2) 50  $\mu$ g pCMVL DNA (63% yield)

were obtained.

### Example 17

#### Intradermal gene delivery of $(C_{10}C^{G+})_2$ /DNA complexes *in vivo*

Complexes were prepared as described in example 16.

To a solution of pCMVL DNA (80 µg in 8 ml of buffer; 30 µM)  $C_{10}C^{G+}$  detergent was added to a final concentration of:

- 1) 21 µM (0.7 eq)
- 2) 30 µM (1.0 eq)
- 3) 37.5 µM (1.25 eq)
- 4) 45 µM (1.5 eq)

After concentration with Vivaspin concentrators, 0.3 ml of complexes containing

- 1) 43 µg pCMVL DNA (53% yield)
- 2) 53 µg pCMVL DNA (65% yield)
- 3) 47 µg pCMVL DNA (58% yield)
- 4) 33 µg pCMVL DNA (41% yield)

were obtained.

The complexes were applied in adequate quantities to introduce 10 µg of pCMVL DNA per mouse in each case.

The following volumes/mouse were injected in the various groups:

- 1) 0.7 eq of  $C_{10}C^{G+}$ /DNA in 70 µl of solution
- 2) 1.0 eq of  $C_{10}C^{G+}$ /DNA in 57 µl solution
- 3) 1.25 eq of  $C_{10}C^{G+}$ /DNA in 64 µl solution
- 4) 1.5 eq of  $C_{10}C^{G+}$ /DNA in 90 µl solution.

For the *in vivo* experiments, female A/J mice aged from 8 to 12 weeks (Harlan) were used. The method of intradermal application of complexes, the preparation of the tissue samples and the quantification of luciferase expression by chemiluminescence assay was the same for all experimental groups. After shaving the backs of the mice one day before, the  $C_{10}C^{G+}$ /Luc

DNA complexes were injected intradermally using (0.40 mm x 21 mm) injection needles. The injection sites were marked. 24 h later, after sacrificing the mice, the injection sites with an average diameter of 15 mm were resected. The skin including the underlying fat tissue was added to 600 µl TRIS buffer and frozen. To quantify luciferase expression, the frozen skin sites were smashed. Afterwards the samples were centrifuged at a temperature of 4°C for 8 min (15000 rpm). Luciferase expression was measured from the supernatant.

Luciferase gene expression (in relative light units / site) at 24 h after injection is shown in Fig. 27 (mean values and STDEV of every group). Similar expression levels were obtained in the range of 0.7 Eq. to 1.25 Eq. of  $C_{10}C^{G+}/DNA$ .

### Example 18

#### Intradermal gene delivery of $(C_{10}C^{G+})_2/DNA$ complexes *in vivo*

Complexes (for group 1) were prepared as described in example 16. To a solution of pCMVL DNA (100 µg in 10 ml of buffer; 30 µM) was added  $C_{10}C^{G+}$  detergent to a final concentration of 30 µM (1 Eq.) and left to oxidize. At the end, 1 ml of 50% glucose was added to bring the solutions to 5% glucose concentration. After concentration with Vivaspin concentrator, 0.4 ml of complex containing 60 µg pCMVL DNA (60 % yield) were obtained.

Group 2) contains 41 µl of the same pCMVL DNA stock solution mixed with 229 µl water (Aqua bidest.) and 30 µl 50 % glucose to get a final concentration of 10 µg pCMVL DNA / 50 µl solution.

For group 3), 2  $\mu$ l of the pCMVL DNA stock solution were added to 268  $\mu$ l water (Aqua bidest.) and 30  $\mu$ l 50% glucose to get a DNA concentration of 0.5  $\mu$ g/50  $\mu$ l.

In the three groups the following amounts of DNA or complexes were applied:

- 1) 1.0 eq  $C_{10}C^{G+}$ /DNA (10  $\mu$ g)
- 2) naked pCMVL DNA (10  $\mu$ g/50  $\mu$ l)
- 3) naked pCMVL DNA (0.5  $\mu$ g/50  $\mu$ l)

The different groups were injected intradermal and the injection sites were obtained 24 h later as described in example 17. Luciferase activity (in relative light units / site) of protein extracts is shown in Fig. 28 (as mean values and STDEV of every group).

### Example 19

Intradermal delivery of  $C_{10}C^{G+}$ /pCMVL/MannITC-PEI(25KDa) complexes *in vivo*

For group 1,  $C_{10}C^{G+}$ /DNA complexes were prepared as described in example 17, followed by coating with mannosylated polyethylenimine (PEI). To a solution of pCMVL DNA (100  $\mu$ g in 10 ml of buffer; 30  $\mu$ M) was added  $C_{10}C^{G+}$  detergent to a final concentration of 30  $\mu$ M (1 eq) and left to oxidize. In the next step, the complex was mixed with 30  $\mu$ g MannITC-PEI (25 kDa) conjugate, the preparation of which is described below, at a molar ratio of PEI nitrogen atoms to DNA phosphate (N/P) of 2.4 and incubated 30 min at room temperature. At the end, 1 ml of 50 % glucose was added to bring the solutions to 5 % glucose concentration. After concentration, 0.25 ml of complex containing 21  $\mu$ g pCMVL DNA (21 % yield) were obtained.

For group 2) analogous complexes, but without  $C_{10}C^{G+}$ , were prepared by mixing pCMVL and MannITC-PEI (25KDa) at a molar ratio of PEI nitrogen atoms to DNA phosphate (N/P) of 2.4. The mixture of 60  $\mu$ g pCMVL DNA in 120  $\mu$ l and 18  $\mu$ g of MannITC-PEI (25KDa) in 150  $\mu$ l were incubated for 20 min (at room temperature). Afterwards 30  $\mu$ l 50 % glucose was added to get a final concentration of 5 % glucose.

Following groups were administered (10  $\mu$ g DNA and 3  $\mu$ g MannoseITC-modified PEI in 50  $\mu$ l/mouse):

- 1)  $C_{10}C^{G+}$ /pCMVL/ MannITC-PEI(25KDa) N/P= 2.4
- 2) pCMVL/ MannITC-PEI (25KDa) N/P= 2.4

Skin sites were obtained 24 h after intradermal injection and luciferase expression was measured. Expression (in relative light units/site) is shown in Fig. 29 (as mean values and STDEV of every group).

MannITC-PEI(25KDa), a conjugate which has mannose linked to PEI via a phenylisothiocyanate bridge, was prepared by using mannopyranosylphenylisothiocyanate (ManITC, Sigma) as coupling reagent. Coupling was performed by reacting 25 mg PEI (25 kDa molecular weight, Aldrich) in 0.33 ml 250 mM aqueous sodium chloride with 25 mg ManITC in 0.2 ml dimethylsulfoxide for at least one day, followed by dilution with 4 ml water and adjustment to 0.5 M sodium chloride, cation exchange chromatography (Biorad Macroprep High S, salt gradient from 0.5 M to 3 M sodium chloride) and dialysis against 150 mM sodium chloride. ManITC-PEI (25KDa) contains PEI/ManITC at a 1.4:1 weight ratio. This represents an average modification of every tenth PEI (25 kDa) nitrogen with mannose.



## Example 20

### Transfection of BNL CL.2 cells with $(C_{12}CO)_2$ /DNA complexes

The solution was prepared by mixing pCMVL (30  $\mu$ M phosphate) with different amounts of the ornithyl-cysteine-dodecylamide detergent  $C_{12}CO$  (Example 4, step 4; 4 eq correspond to 60  $\mu$ M  $C_{12}CO$ ) in Tris/HCl 15 mM pH 8.4 buffer and leaving the solution in aerobic condition during 24 h. Cells were seeded at 50.000 cells per well in 24-well dishes 18 h before transfection. An aliquot of the complex mixture (corresponding to 2  $\mu$ g plasmid per well) was added to the cells maintained in serum-free DMEM medium. After 2.5 h 10 % of serum was added. Luciferase gene expression was monitored 24 h later. The results are shown in Fig. 30.

## References

1. Mulligan, R.C. The Basic Science of Gene Therapy. *Science* 260, 926-932 (1993).
2. Tang, M.X. & Szoka, F.C. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. *Gene Therapy* 4, 823-832 (1997).
3. Labatmoleur, F., Steffan, A.M., Brisson, C., Perron, H., Feugeas, O., Furstenberger, P., Oberling, F., Brambilla, E. & Behr, J.P. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. *Gene Therapy* 3, 1010-1017 (1996).
4. Behr, J.P. DNA strongly binds to micelles and vesicles containing lipopolyamines or lipointercalants. *Tet. Letters* 27, 5861-5864 (1986).
5. Melnikov, S.M., Sergeyev, V.G. & Yoshikawa, K. Discrete coil-globule transition of large DNA induced by cationic surfactant. *J Am Chem Soc* 117, 2401-2408 (1995).
6. Behr, J.P. Synthetic gene-transfer vectors. *Accounts Chem. Res.* 26, 274-278 (1993).
7. Lehn, J.M. Supramolecular chemistry-Scope and perspectives: Molecules, supermolecules and molecular devices (Nobel lecture). *Angew. Chem. Int. Ed. Engl.* 27, 89-112 (1988).
8. Ringsdorf, H., Schlarb, B. & Venzmer, J. Molecular architecture and function of polymeric oriented systems: Models for the study of organization, surface recognition and dynamics of biomembranes. *Angew. Chem. Int. Ed. Engl.* 27, 113-158 (1988).
9. Gustafsson, J., Arvidson, G., Karlsson, G. & Almgren, M. Complexes between cationic liposomes and DNA visualized by cryo-TEM. *Biochim. Biophys. Acta* 1235, 305-312 (1995).
10. Remy, J.S., Kichler, A., Mordvinov, V., Schuber, F. & Behr, J.P. Targeted gene transfer into hepatoma cells with lipopolyamine-

condensed DNA particles presenting galactose ligands: A stage toward artificial viruses. *Proc Natl Acad Sci USA* 92, 1744-1748 (1995).


11. Fields, B.N. & Knipe, D.M. *Virology* (Raven Press, New York, 1990).
12. Boussif, O., Lezoualch, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B. & Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. *Proc Natl Acad Sci USA* 92, 7297-7301 (1995).
13. Riddles, P.W., Blakeley, R.L. & Zerner, B. Ellman's reagent: 5, 5'-dithiobis(2-nitrobenzoic acid); a reexamination. *Anal. Biochem.* 94, 75-81 (1979).
14. Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E. (1994) *J. Biol. Chem.* 269, 12918-12924.
15. Mechtler, K. and Wagner, E. (1997), *New J. Chemistry* 21, 105-111.
16. Gottschalk, S., Sparrow, J.T., Hauer, J., Mims, M.P., Leland, F.E., Woo, S.L.C. and Smith, L.C. (1996) *Gene Therapy* 3, 448-457.
17. Wyman, T.B., Nicol, F., Zelphati, O., Scaria, P.V., Plank, C., and Szoka, F.C. (1997) *Biochemistry* 36, 3008-3017.
18. Legendre, J. Y., and Szoka, F. C. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90, 893,.
19. Legendre, J.Y., and Supersaxo, A. (1995) *Biochem. Biophys. Res. Commun.* 217, 179-85.
20. Wilson, P.D., Firestone, R.A., and Lenard, J (1987) *J. Cell.Biol.* 104, 1123-1229.
21. Hughes, J.A., Aronsohn, A.I., Avrutskaya, A.V., and Juliano, R.L. (1996) *Pharm. Res.* 13, 404-410.
22. Remington's Pharmaceutical Sciences (1980), Mack Publishing Co., Easton, PA, Osol (ed.)
23. Zanta, M.A. (1997) *Bioconjugate Chem.*, 8, 839-844
24. Blessing et al. (1998) *Proc.Natl. Acad. Sci. USA*, 95 (4), 1427-1431

## Claims

1. A particle for transfecting higher eucaryotic cells with nucleic acid molecules *in vitro* and *in vivo* comprising one or more nucleic acid molecules condensed by organic cationic molecules, said particles being obtained by complexing the nucleic acid molecules with identical or different organic cationic precursor molecules without crosslinking nucleic acid molecules, and covalently linking the precursor molecules to each other on the the nucleic acid template.
2. The transfection particle of claim 1, wherein the cationic molecules are lipids obtained by dimerization or oligomerization of cationic detergent precursor molecules.
3. The transfection particle of claim 2, wherein the cationic detergent precursor molecules comprise:
  - a) at least one function for binding to one or more other detergent molecules,
  - b) at least one lipophilic residue,
  - c) a non-toxic recipient backbone,
  - d) a cationic group for binding to nucleic acid molecules.
4. The transfection particle of claim 3, wherein the function of the cationic precursor detergent molecules for binding to other detergent molecules is a dimerizable or polymerizable function selected from

thiols, acid hydrazides, aldehydes, amines, and ethylene residues that are suitably substituted to provide enamines.

5. The transfection particle of claim 4, wherein the lipophilic residue is selected from lipophilic amides, esters or ethers.
6. The transfection particle of claim 3, wherein the function for binding to nucleic acid molecules is selected from an amine or derivative thereof.
7. The transfection particle of claim 6, wherein the function for binding to nucleic acid molecules is guanidine.
8. The transfection particle of claim 1, wherein the organic cationic precursor molecule is represented by general formula I



(I)

wherein

$R_1$  denotes  $(C_1-C_{10}\text{-alkylene})\text{-SH}$ , wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

$R_2$  denotes  $-\text{NR}_4\text{R}_5$ ,  $-\text{NHR}_4\text{R}_5^+$ ,  $-\text{N}(\text{R}_4)_2\text{R}_5^+$ ,  $-\text{C}(=\text{NR}_4)\text{NR}_5\text{R}_6$ ,  $-\text{C}(=\text{X})\text{-C}_1\text{-C}_{10}\text{-alkylene}$ , wherein the alkylene radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four dialkyl amino groups or a thiomonosaccharide;

$R_3$  denotes  $\text{C}_5\text{-C}_{30}\text{-alkyl}$ , straight chained or branched and

optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>5</sub>-C<sub>30</sub>-alkenyl, straight chained or branched having up to ten C=C-double bonds and is optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>5</sub>-C<sub>30</sub>-alkinyl, straight chained or branched having up to ten C≡C-triple bonds and is optionally substituted preferably with one or more halogen atom(s) or dialkyl amino group(s), or

C<sub>6</sub>-C<sub>10</sub>-aryl optionally substituted, or

C<sub>7</sub>-C<sub>16</sub>-aralkyl optionally substituted, or a

C<sub>5</sub>-C<sub>30</sub>-alkyl-chain interrupted by up to 10 amino groups -NR<sub>4</sub>- and having optionally an amino-group which is optionally substituted by an amino acid;

R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> denote independently from each other hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

X denotes O or S;

Y denotes C=O or C=S and

Z denotes O, S or -NR<sub>4</sub>-.

9. The transfection particle of claim 8, wherein the cationic precursor molecules correspond to general formula I, wherein

$R_1$  denotes (C<sub>1</sub>-C<sub>6</sub>-alkylene)-SH, wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

$R_2$  denotes -NR<sub>4</sub>R<sub>5</sub>, -NHR<sub>4</sub>R<sub>5</sub><sup>+</sup>, -N(R<sub>4</sub>)<sub>2</sub>R<sub>5</sub><sup>+</sup>, -C(=NR<sub>4</sub>)NR<sub>5</sub>R<sub>6</sub>, -C(=X)-C<sub>1</sub>-C<sub>4</sub>-alkylene, wherein the alkylene radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four amino radicals -NR<sub>4</sub>R<sub>5</sub> or a thiomonosaccharide;

$R_3$  denotes C<sub>5</sub>-C<sub>20</sub>-alkyl, straight chained or branched and optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>5</sub>-C<sub>20</sub>-alkenyl, straight chained or branched having up to five C=C-double bonds and is optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>5</sub>-C<sub>20</sub>-alkinyl, straight chained or branched having up to five C≡C-triple bonds and is optionally substituted preferably with F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>6</sub>-C<sub>10</sub>-aryl optionally substituted preferably with C<sub>1</sub>-C<sub>4</sub>-alkyl, F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

C<sub>7</sub>-C<sub>14</sub>-aralkyl optionally substituted preferably with C<sub>1</sub>-C<sub>4</sub>-alkyl, F, Cl, Br or -NR<sub>4</sub>R<sub>5</sub>, or

a C<sub>5</sub>-C<sub>20</sub>-alkyl chain interrupted by up to 10 amino groups -NR<sub>4</sub>- and having optionally a -amino-group which is optionally substituted by an amino acid;

$R_4$ ,  $R_5$  and  $R_6$  denote independently from each other hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

X denotes O or S;

Y denotes C=O or C=S and

Z denotes O, S or -NR<sub>4</sub>-.

10. The transfection particle of claim 8, wherein the cationic precursor molecules correspond to general formula I, wherein

R<sub>1</sub> denotes (C<sub>1</sub>-C<sub>4</sub>-alkylene)-SH, wherein the alkylene radical may represent a straight chained or branched hydrocarbon;

R<sub>2</sub> denotes -NR<sub>4</sub>R<sub>5</sub>, -NHR<sub>4</sub>R<sub>5</sub><sup>+</sup>, -N(R<sub>4</sub>)<sub>2</sub>R<sub>5</sub><sup>+</sup>, -C(=NR<sub>4</sub>)NR<sub>5</sub>R<sub>6</sub>, -C(=X)-C<sub>1</sub>-C<sub>4</sub>-alkyl, wherein the alkyl radical may represent a straight chained or branched hydrocarbon and may be substituted by up to four amino radicals -NR<sub>4</sub>R<sub>5</sub>, or a thiomonosaccharide;

R<sub>3</sub> C<sub>5</sub>-C<sub>12</sub>-alkyl, straight chained or branched and optionally substituted preferably with F, Cl, Br or -NH<sub>2</sub>, or a

C<sub>5</sub>-C<sub>15</sub>-alkyl chain interrupted by up to 7 amino groups -NR<sub>4</sub>- and having optionally a -amino-group which is optionally substituted by the amino acid cysteine;

R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> denote independently from each other hydrogen or methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl or tert.-butyl;

X denotes O or S;

Y denotes C=O or C=S and



Z denotes O, S or -NR<sub>4</sub>-.

11. The transfection particle of claim 8, wherein the cationic precursor molecules correspond to the general formula I, wherein

R<sub>1</sub> denotes -CH<sub>2</sub>-SH;

R<sub>2</sub> denotes -NH<sub>2</sub>, -NH<sub>3</sub><sup>+</sup>, -C(=N<sup>+</sup>H<sub>2</sub>)NH<sub>2</sub>, -C(=O)-C<sub>1</sub>-C<sub>4</sub>-alkyl straight chained or branched and optionally substituted with F, Cl, Br or -NH<sub>2</sub>,  
or an ornithine radical or a S-galactosyl radical;

R<sub>3</sub> denotes a C<sub>6</sub>-C<sub>15</sub>-alkyl radical straight chained or branched and optionally substituted preferably with F, Cl, Br or -NH<sub>2</sub>;

Y denotes C=O;

Z denotes O or -NH-.

12. The transfection particle of one of claim 8 to 11, wherein R<sub>2</sub> is guanidine ornithine.
13. The transfection particle of one of claim 8 to 12, wherein R<sub>3</sub> is a decyl radical.
14. The transfection particle of one of claim 8 to 11, wherein R<sub>1</sub> is a methylenethiol, R<sub>2</sub> is a guanidine, R<sub>3</sub> is a straight chained decyl radical, Y is a carbonyl, Z is an amine, and pharmaceutically acceptable salts thereof.

15. The transfection particle of claim 14, wherein the cationic molecule is N-decyl-2-guanidinium-cysteine.
16. The transfection particle of one of claim 8 to 11, wherein R<sub>1</sub> is a methylenethiol, R<sub>2</sub> is an ornithine, R<sub>3</sub> is a decane, Y is a carbonyl, Z is an amine, and pharmaceutically acceptable salts thereof.
17. The transfection particle of claim 16, wherein the cationic molecule is N-decyl-2-ornithinyl-cysteine.
18. The transfection particle of one of claim 8 to 11, wherein the monosaccharide which is bonded via a sulfur atom is selected from the group consisting of galactose, lactose, glucose, arabinose, fructose, sorbose, xylose, ribose, mannose each of them in their D- or L-form.
19. The transfection particle of claim 1, wherein the cationic precursor molecule is a polyamine.
20. The transfection particle of claim 19, wherein the cationic precursor molecule is a spermine derivative.
21. The transfection particle of claim 20, wherein the cationic precursor molecule is spermine-N1,N12-bis-cysteineamide.
22. The transfection particle of claim 1 to 21, wherein the linkage between the cationic molecules is degradable under cellular conditions.
23. The transfection particle of claim 1 which comprises a single nucleic acid molecule.

24. The transfection particle of claim 1 or 23, wherein the nucleic acid molecule is a DNA molecule.
25. The transfection particle of claim 24, wherein the DNA molecule is a plasmid.
26. The transfection particle of claim 1, wherein the nucleic acid molecule is an RNA molecule.
27. The transfection particle of any one of claims 1 to 26, characterized in that it carries one or more cellular targeting functions and/or one or more functions capable of facilitating endocytosis.
28. The transfection particle of claim 27, wherein said functions are linked to the cationic molecules.
29. The transfection particle of claim 27, wherein said functions are linked to nucleic acid binding molecules that are present in addition to the cationic molecules.
30. The transfection particle of claim 27, wherein the targeting function is a cellular protein ligand.
31. The transfection particle of claim 27, wherein the targeting function is a sugar residue.
32. The transfection particle of claim 31, wherein the sugar is galactose.
33. The transfection particle of claim 31, wherein the sugar is mannose.

34. The transfection particle of claim 1, characterized in that it carries one or more endosomolytic functions.
35. The transfection particle of claim 34, wherein said endosomolytic functions are linked to the cationic molecules.
36. The transfection particle of claim 34, wherein said functions are linked to nucleic acid binding molecules that are present in addition to the cationic molecules.
37. The transfection particle of claim 34, wherein the endosomolytic function is a fusogenic peptide.
38. The transfection particle of claim 34, wherein the endosomolytic function is a virus.
39. The transfection particle of claim 38, wherein the virus is an adenovirus.
40. A method for preparing transfection particles of any of claims 1 to 39, wherein cationic precursor molecules are added to nucleic acid molecules in a suitable buffer, allowed to form complexes with the nucleic acid and allowed to covalently link to identical or different cationic precursor molecules on the nucleic acid template.
41. The method of claim 40, wherein the cationic precursor molecules are lipophilic and are allowed to covalently link under mild oxidative conditions.

42. A pharmaceutical composition comprising a pharmaceutically effective amount of the transfection particle of claim 1, wherein the nucleic acid molecule is therapeutically active.
43. The pharmaceutical composition of claim 42, wherein the nucleic acid molecule is a plasmid encoding a therapeutically active protein.
44. A method for introducing therapeutically active nucleic acid into a mammal, wherein a transfection particle of claim 1 is administered to said mammal intradermally.
45. A kit of parts comprising one or more nucleic acid molecules, one or more cationic precursor molecules, suitable buffers, and other reagents or mechanical devices that are useful for preparation, purification and *in vitro* or *in vivo* application of a transfection particle of any one of the claims 1 to 39.
46. The kit of parts of claim 45 comprising in addition or more functions for cellular targeting.
47. The kit of parts of claim 45 comprising in addition once or more endosomolytic functions.

### Abstract

**Transfection particles for delivery of nucleic acid into higher eucaryotic cells *in vitro* and *in vitro* comprises one or more nucleic acid molecules condensed by organic cationic molecules. The discrete and stable particles are obtained by complexing the nucleic acid molecules with identical or different organic cationic precursor molecules without crosslinking nucleic acid molecules, and covalently linking the precursor molecules to each other on the nucleic acid template. For specific cellular targeting, the particles may carry targeting molecules, e.g. sugars. Preferred cationic precursor molecules are lipophilic detergents that are linked to form lipids. The particles contain preferably only one nucleic acid molecule which makes them useful for gene therapy and for delivery of large DNA molecules.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Behr *et al.*

Appl. No. 09/555,574

U.S. Nat'l Phase of PCT/EP98/07695

I.A. Filing Date: November 28, 1998

For: **Transfection Particles**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket:  
0652.2090000/EKS/JMC/ALS

**Batch No.**

**Letter to PTO Draftsman: Submission of Formal Drawings**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith are thirty four (34) sheets of formal drawings with Figures 1-3, 4A-D, 5, 6A-C, 7A, 7B, 8, 9, 10, 11A, 11B, 12-15, 16A-C, 17-30, corresponding to the informal drawings submitted with the above-captioned application. The application number, group art unit and attorney docket number appear on the back of each sheet. Acknowledgment of the receipt, approval, and entry of these formal drawings into this application is respectfully requested.

It is not believed that an extension of time is required, other than any already provided herewith. However, if an extension of time is needed to prevent abandonment of the application, then such extension of time is hereby petitioned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this Letter is enclosed.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




John M. Covert  
Attorney for Applicants  
Registration No. 38,759


Date: Oct. 23, 2000

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600


1/34  
Fig. 1




2/34  
Fig. 2


3/34  
Fig. 3

4/34  
Fig. 4




5/34  
Fig. 5


6/34  
Fig. 6A




7/34  
Fig. 6B




8/34  
Fig. 6C





9/34  
Fig. 7A






10/34  
Fig. 7B

11/34  
Fig. 8


12/34  
Fig. 9




14/34  
Fig. 11A




15/34  
Fig. 11B



16/34  
Fig. 12





17/34  
Fig. 13



18/34

Fig. 14



19/34  
Fig. 15

20/34

Fig. 16A




Fig. 16B







Fig. 16C





21/34  
Fig. 17


22/34  
Fig. 18



23/34  
Fig. 19




24/34  
Fig. 20


25/34  
Fig. 21




26/34  
Fig. 22




27/34  
Fig. 23



28/34  
Fig. 24




29/34  
Fig. 25




30/34

Fig. 26




31/34

Fig. 27




32/34

Fig. 28




33/34

Fig. 29





34/34  
Fig. 30

## Declaration for Patent Application

Docket Number: 0652.2090000/REF/ALS

As a below named inventor, I hereby declare that:

BI Ref. No: Case 12/194-US

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Transfection Particles, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on June 1, 2000;  
as United States Application Number 09/555,574 or National Stage of PCT International Application Number PCT/EP98/07695; and  
was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed
<u>EP 97 121 308.7</u> ✓ (Application No.)	<u>Europe</u> ✓ (Country)	<u>December 4, 1997</u> ✓ (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____ (Application No.)	_____ (Filing Date)
_____ (Application No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/EP98/07695</u> ✓ (Application No.)	<u>November 28, 1998</u> ✓ (Filing Date)	_____ (Status - patented, pending, abandoned)
_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00	Full name of sole or first inventor <u>Jean-Paul REHR</u>	
	Signature of sole or first inventor <u>Jean Paul Rehr</u>	<u>September 28, 2000</u> Date
	Residence <u>Strasbourg, France FRX</u>	
	Citizenship <u>FR</u>	
	Post Office Address <u>7, rue Eugénie, F-67100 Strasbourg, France</u>	
2-00	Full name of second inventor <u>Thomas BLESSING</u>	
	Signature of second inventor <u>Thomas Blessing</u>	<u>Sept. 15, 2000</u> Date
	Residence <u>Wien, AT ATX</u>	
	Citizenship <u>FR</u>	
	Post Office Address <u>Am Hofgärtel 8/4/24, A-1110 Wien, Austria</u>	
3-00	Full name of third inventor <u>Ernst WAGNER</u>	
	Signature of third inventor <u>Ernst Wagner</u>	<u>Sept 13, 2000</u> Date
	Residence <u>Langenzersdorf, AT ATX</u>	
	Citizenship <u>AT</u>	
	Post Office Address <u>Wiener Strasse 201, A-2103 Langenzersdorf, Austria</u>	

4-00

Full name of sole or fourth inventor <u>Susanne SCHUELLER</u>
Signature of sole or fourth inventor <i>Susanne Schueller</i> Date <i>Sept. 13, 2000</i>
Residence <u>Wien, AT ATX</u>
Citizenship <u>AT</u>
Post Office Address <u>Himmelschlüsselweg 7, A-1160 Wien, Austria</u>

(Supply similar information and signature for subsequent joint inventors, if any)

3/2/98

12/194

# POWER OF ATTORNEY FROM ASSIGNEE

Boehringer Ingelheim International GmbH, a corporation of Germany, having a principal place of business at D-55216 Ingelheim am Rhein, GERMANY, is co- assignee of entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee from **Thomas BLESSING, Ernst WAGNER, and Susanne SCHUELLER** executed on Sept 15, 2000; Sept 13, 2000; Sept 13, 2000 of an invention known as Transfection Particles (Attorney Docket No. 0652.2090000/REF/ALS), which is disclosed and claimed in a patent application of the same title by the inventor(s) Jean-Paul Behr, Thomas BLESSING, Ernst WAGNER, and Susanne SCHUELLER (said application filed on June 1, 2000 at the U.S. Patent and Trademark Office, having Application Number 09/555,574 ).

Jane  
Reg. No.  
38,759

The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; Samuel L. Fox, Esq., Reg. No. 30,353; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,103; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; Raz E. Fleshner, Esq., Reg. No. 34,331; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Boehringer Ingelheim International GmbH  
ppa. [Signature] ppa. [Signature]  
SIGNATURE: Dr. Dieter LAUDIEN Dr. Heinz-Gerd KLÄS  
BY: Head of Patent Division Head of Patent Department  
TITLE: \_\_\_\_\_  
DATE: Sept. 12, 2000

# POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Université Louis Pasteur de Strasbourg, a university of France, having a principal place of business at 4, rue Blaise Pascal, F-67000 Strasbourg, France, is co-assignee of entire right, title, and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee from Jean-Paul BEHR executed on Sept. 2, 2000 of an invention known as Transfection Particles (Attorney Docket No. 0652.2090000/REF/ALS), which is disclosed and claimed in a patent application of the same title by the inventor(s) Jean-Paul BEHR, Thomas BLESSING, Ernst WAGNER, and Susanne SCHUELLER (said application filed on June 1, 2000 at the U.S. Patent and Trademark Office, having Application Number 09/555,574).

Jmc  
Reg No.  
38,759

16- The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Registration No. 25,688; Jorge A. Goldstein, Registration No. 29,021; Samuel L. Fox, Registration No. 30,353; David K.S. Cornwell, Registration No. 31,944; Robert W. Esmond, Registration No. 32,893; Tracy-Gene G. Durkin, Registration No. 32,831; Michele A. Cimbala, Registration No. 33,851; Michael B. Ray, Registration No. 33,997; Robert E. Sokohl, Registration No. 36,013; Eric K. Steffe, Registration No. 36,688; Michael Q. Lee, Registration No. 35,239; Steven R. Ludwig, Registration No. 36,203; Raz E. Fleshner, Registration No. 34,331; John M. Covert, Registration No. 38,759; and Linda E. Alcorn, Registration No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Boehringer Ingelheim GmbH as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the person(s) from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.

FOR: ULP  
SIGNATURE: [Signature]  
BY: LLERENA Patrice  
TITLE: V. President ULP  
DATE: Sept 29, 2000